Kansas Sues Tobacco Companies
Kansas is one of the latest states to sue the nation's leading
tobacco companies to recover health care costs incurred because of the
harmful effects of cigarette smoke. The Kansas suit also cites
violations of the state's Consumer Protection Act stemming from what
it alleges were deceptive trade practices used by the tobacco industry
in denying consumers accurate information on the health risks of
smoking.
IN THE DISTRICT COURT OF SHAWNEE COUNTY, KANSAS
DIVISION
STATE OF KANSAS, ex rel.
CARLA J. STOVALL, Attorney General,
Plaintiff,
v.
R.J. REYNOLDS TOBACCO
COMPANY; PHILIP MORRIS,
INCORPORATED;
BROWN & WILLIAMSON TOBACCO
CORPORATION;
B.A.T. INDUSTRIES, P.L.C.;
LORILLARD TOBACCO COMPANY;
THE AMERICAN TOBACCO
COMPANY; HILL & KNOWLTON,
INC.; THE COUNCIL FOR TOBACCO
RESEARCH-U.S.A., INC.;
THE TOBACCO INSTITUTE, INC.;
and JOHN DOE ENTITIES "A"
THROUGH "Z."
Defendants.
Case No. 96-CV-
PETITION
(Filed Pursuant to K.S.A. Chapter 60)
COMES NOW the State of Kansas, on the relation of Carla J. Stovall,
Attorney General (hereinafter "the State" or "Kansas")? and for its
causes of action against the Defendants herein allege, state, and aver
as follows:
I.
Parties
1.Plaintiff, State of Kansas is a body politic governed by the
Constitution and laws of Kansas, and is entitled to bring this action
pursuant to the laws of Kansas. This suit concerns significant matters
of state-wide public interest and is brought on the relation of the
Attorney General, pursuant the Attorney General's other
constitutional, statutory, and common law powers to act on behalf of
the State and certain of its agencies. The State seeks, among other
forms of relief, the specific measures set forth below:
a. Consumer Protection Enforcement. The Attorney General has broad
authority to institute actions under the Kansas Consumer Protection
Act to safeguard Kansas citizens from, among other things,
unconscionable and deceptive acts and practices, including the use of
false and misleading advertising campaigns and the marketing of
dangerous products to minors. Under this authority, the Attorney
General seeks civil penalties, restitution, and appropriate declaratory
and injunctive relief, including but not limited to a permanent
injunction to require Defendants to cease marketing tobacco products
to children, to disclose their knowledge of and research into smoking,
addiction, and the impact of smoking on health, to publish corrective
advertising, to fund a public education campaign on the health
consequences of smoking as well as smoking cessation programs for
nicotine-dependent smokers, other remedial measures, investigative
fees and expenses, and other appropriate relief.
b. Restraint of Trade. Kansas law (Restraint of Trade, K.S.A. 50-101
et seq.), herein referred to as the "Kansas Antitrust Act") gives the
Attorney General broad powers to protect the public and foster fair
and honest intrastate competition by instituting actions against persons
who conspire to restrain trade and commerce or monopolize markets
in Kansas. Under this authority, the Attorney General seeks civil
penalties and appropriate injunctive relief, including but not limited to
a permanent injunction to require Defendants to disclose their
knowledge of and research into smoking, addiction and the impact of
smoking on health.
c. Medical Costs. Among other things, the State seeks restitution for
the smoking-related health care costs paid by the State through its
various statutory medical programs, including the programs
established pursuant to K.S.A. 39-701 et. seq. For example, under
the Kansas Medicaid program, K.S.A. 39-708c(s) and K.S.A. 39-
709, the State, in financial partnership with the federal government,
provides financial assistance for a broad range of health care services
to eligible low income Kansas residents. A significant portion of the
monies that the State has paid out, and will continue to pay out, to
recipients under the Kansas Medicaid program is for health care costs
attributable to smoking-related illnesses and diseases. Additionally,
the State expends large sums of money for the provision of health care
to eligible citizens under various other State programs, which health
care costs are attributable to smoking-related illnesses and diseases.
2. Defendant Philip Morris, Incorporated (Philip Morris U.S.A.)
(hereinafter "Philip Morris") is a Virginia corporation whose principal
place of business is located at 120 Park Avenue, New York, New
York 10016 and may be served with process pursuant to K.S.A. 60-
308(e) at that address. Defendant Philip Morris, Incorporated (Philip
Morris U.S.A.) manufactures, advertises, promotes, markets and
sells Philip Morris, Merit, Cambridge, Marlboro, Benson & Hedges,
Virginia Slims, Alpine, Dunhill, English Ovals, Galaxy, Players,
Saratoga and Parliament cigarettes throughout the United States,
including in Kansas.
3. Defendant R.J. Reynolds Tobacco Company (hereinafter "R.J.
REYNOLDS") is a New Jersey corporation whose principal place of
business is located at Fourth and Main Streets, Winston-Salem, North
Carolina 27102 and may be served with process pursuant to K.S.A.
60-308(e) at that address. Defendant R.J. Reynolds manufactures,
advertises, promotes, markets and sells Camel, Vantage, Now, Doral,
Winston, Sterling, Magna, More, Century, Bright Rite and Salem
cigarettes throughout the United States, including in Kansas.
4. Defendant Brown & Williamson Tobacco Corporation (hereinafter
"Brown & Williamson") is a Delaware corporation, with its principal
place of business at 1500 Brown & Williamson Tower, Louisville,
Kentucky 40232 and may be served with process pursuant to K.S.A.
60-308(e) at that address. Defendant Brown & Williamson Tobacco
Corporation is a subsidiary or division of Batus Holdings, Inc. and
Defendant B.A.T. Industries, P.L.C. Defendant Brown & Williamson
Tobacco Corporation manufactures, advertises, promotes, markets
and sells Kool, Barclay, BelAir, Capri, Raleigh, Richland, Laredo,
Eli Cutter and Viceroy cigarettes throughout the United States,
including in Kansas.
5. Defendant B.A.T. Industries, P.L.C. (hereinafter "B.A.T.
Industries") is a British corporation with its principal place of business
at Windsor House, 50 Victoria Street, London, England SWIH ONL
and may be served with process at said address pursuant to the Hague
Convention through Plaintiff's counsel. Through a succession of
intermediary corporations and holding companies, Defendant B.A.T.
Industries, P.L.C. is the sole shareholder of Defendant Brown &
Williamson Tobacco Corporation. Through Defendant Brown &
Williamson Tobacco Corporation, Defendant B.A.T. Industries,
P.L.C. has placed cigarettes into the stream of commerce with the
expectation and the intention that substantial sales of cigarettes would
be made in the United States, including in Kansas. In addition,
Defendant B.A.T. Industries, P.L.C. as a principal, or through its
agents and/or co-conspirators, conducted significant and critical
research for Defendant Brown & Williamson Tobacco Corporation on
the issues of smoking and health in humans. Further, Defendant
Brown & Williamson Tobacco Corporation is believed to have sent to
England the results of research that it conducted in the United States
on the issue of smoking and health in humans in an attempt to remove
sensitive and inculpatory documents from the jurisdiction of United
States courts in Kansas and elsewhere. These documents were and are
subject to the control of Defendant B.A.T. Industries, P.L.C.
Defendant B.A.T. Industries, P.L.C. has been involved in the
conspiracy alleged herein and the actions of Defendant B.A.T.
Industries, P.L.C. have effected and caused harm in Kansas.
6. Defendant Lorillard Tobacco Company (hereinafter "Lorillard") is a
Delaware corporation whose principal place of business is located at 1
Park Avenue, New York, New York 10016 and may be served with
process pursuant to K.S.A. 60- 308(e) at that address. Defendant
Lorillard Tobacco Company manufactures, advertises, promotes,
markets and sells Old Gold, Kent, Triumph, Satin, Max, Spring,
Newport and True cigarettes throughout the United States, including
in Kansas.
7. Defendant The American Tobacco Company (hereinafter "American
Tobacco") is a Delaware corporation whose principal place of
business is located at Six Stamford Forum, Stamford, Connecticut
06904 and may be served with process pursuant to K.S.A. 60-308(e)
at that address. Defendant The American Tobacco Company is or was
a subsidiary or division of American Brands, Inc. Defendant The
American Tobacco Company manufactures, advertises, promotes,
markets and sells Lucky Strike, Pall Mall, Tareyton, Malibu,
American, Montclair, Newport, Misty, Barclay, Iceberg, Silk Cut,
Silva Thins, Sobrania, Bull Durham and Carlton cigarettes throughout
the United States, including in Kansas. On December 21, 1994,
Defendant The American Tobacco Company was purchased by
Defendant B.A.T. Industries, P.L.C. who, on information and belief,
has succeeded to the liabilities of Defendant The American Tobacco
Company by operation of law, or as a matter of fact.
8. Defendant Hill & Knowlton, Inc. (hereinafter "Hill & Knowlton")
is a New York corporation whose principal place of business is
located at 420 Lexington Avenue, New York, New York 10070 and
may be served with process pursuant to K.S.A. 60-308(e) at that
address. Defendant Hill & Knowlton, Inc. is an international public
relations firm. Defendant Hill & Knowlton, Inc. played an active and
knowing role in the conspiracy complained of herein by aiding the
circulation and/or publication of many false statements of the tobacco
industry attributable to the Tobacco Industry Research Committee and
the Defendant Council for Tobacco Research.
9. Defendant The Council for Tobacco Research - U.S.A., Inc.
(hereinafter "CTR"), successor in interest to the Tobacco Industry
Research Committee ("TIRC"), is a nonprofit corporation organized
under the laws of the State of New York with its principal place of
business at 900 3rd Avenue, New York, New York 10022 and may
be served with process pursuant to K.S.A. 60-308(e) at that address.
Defendant The Council for Tobacco Research-U.S.A., Inc. was
created by the tobacco company defendants to disseminate false
information regarding the health risks and hazards of smoking.
10. Defendant The Tobacco Institute, Inc. (hereinafter "Tobacco
Institute") is a New York corporation whose principal place of
business is located at 1875 "I" Street, N.W., Suite 800, Washington,
D.C. 20006 and may be served with process pursuant to K.S.A. 60-
308(c) at that address. Defendant The Tobacco Institute, Inc. has since
its incorporation in 1958, operated as the public relations and lobbying
arm of the Tobacco Companies.
11. Defendants John Doe Entities "A" Through "Z" are business
entities, both Kansas and foreign, whose identities are presently
unknown to the State but who may be described as certain
manufacturers and distributors, and/or certain of their trade
organizations, public relations firms, law firms and other such entities
that, at all pertinent times, manufactured, tested, designed, promoted,
marketed, packaged, sold, distributed, and/or purposely placed into
the stream of commerce in and into the State, various brands of
cigarettes, or, in the course of business, materially participated with,
conspired with and/or otherwise aided, abetted and assisted others in
so doing, all to the detriment of the State as alleged herein.
12. The defendants listed herein, and/or their predecessors and/or their
successors in interest, are either organized under the laws of (i)
Kansas or (ii) a state other than Kansas, or (iii) are partnerships or
other unincorporated associations with principal places of business
both within and without Kansas and are each subject to suit. All
Defendants have established relationships with the State within the
contemplation of the Kansas Statutes Annotated adequate to constitute
a sufficient basis of personal jurisdiction under K.S.A. 60-308(b).
13. Philip Morris Incorporated (Philip Morris U.S.A.), R.J.
Reynolds Tobacco Company, Brown & Williamson Tobacco
Corporation, B.A.T. Industries, P.L.C., Lorillard Tobacco
Company, The American Tobacco Company, Liggett Group, Inc. and
certain of the "A" Through "Z" entities (Doe Defendants) collectively
are referred to hereinafter as "The Tobacco Companies."
14. The Council for Tobacco Research-U.S.A. Inc., (successor to
The Tobacco Institute Research Committee) and The Tobacco
Institute, Inc., collectively are referred to hereinafter as "The Tobacco
Trade Associations."
15. Hill & Knowlton, Inc. and certain of the "A" through "Z" entities
(Doe Defendants) collectively are referred to hereinafter as "The
Tobacco Consultants. "
16. Shook, Hardy & Bacon, P.C. and Jacob, Medinger & Finnegan
and certain of the "A" Through "Z" entities (Doe Defendants)
collectively are referred to hereinafter as "The Tobacco Attorneys."
17. At all pertinent times, Defendants acted through their duly
authorized agents, servants, and employees who were then acting in
the course and scope of their employment, and in furtherance of the
businesses of said Defendants. At all pertinent times, the Tobacco
Attorneys and the Tobacco Trade Associations were the agents,
servants, and/or employees of the Tobacco Companies and acted
within the scope of said agency, servitude and/or employment. At all
pertinent times, the Tobacco Consultants were the agents, servants,
and/or employees of the Tobacco Companies and/or the Tobacco
Trade Associations and acted within the scope of said agency,
servitude and/or employment.
18. The Defendants listed above, and/or their predecessors and
successors in interest, did business in the State of Kansas; made
contracts to be performed in whole or in part in Kansas; and/or
manufactured, tested, sold, offered for sale, supplied or placed in the
stream of commerce, or in the course of business materially
participated with others in so doing, cigarettes which the defendants
knew to be defective, unreasonably dangerous and hazardous.
Defendants further knew such cigarettes would be substantially certain
to cause injury to the State and to persons within the State thereby
negligently and/or willfully and or intentionally causing injury to
persons within Kansas and to the State, and as described herein,
committed and continue to commit tortious and other unlawful acts in
and with consequences in the State of Kansas.
19. Each Defendant is sued individually as a primary violator and as a
coconspirator and aider and abettor, and the liability of each arises
from the fact that each Defendant entered into an agreement with the
other Defendants and third parties to pursue, and knowingly pursued,
the common course of conduct to commit or participate in the
commission of all or part of the unlawful acts, tortious acts, plans,
schemes, transactions, and artifices to defraud and/or deceive and/or
mislead alleged herein.
20. Such acts of conspiracy and aiding and abetting included, among
other things, falsely advertising, marketing, promoting and selling
cigarettes as safe, non-addictive, and not containing levels of nicotine
manipulated by Defendants to cause and maintain addiction.
21. The liability of each Defendant arises from the fact that each
committed and/or engaged in a conspiracy to accomplish the
commission of all or part of the unlawful and/or tortious conduct
alleged herein, and/or intentionally, and/or willfully, knowingly, with
evil motive, intent to injure, ill will and/or fraud and without legal
justification or excuse, engaged in the conduct herein alleged.
22. The Defendants, and/or their predecessors and successors in
interest, performed such acts as were intended to, and did, result in
the sale and distribution of cigarettes and other tobacco products in the
State of Kansas and the use and consumption of cigarettes and other
tobacco products by residents of the State of Kansas.
23. The term "addictive" used in this Petition is synonymous and
interchangeable with the term "dependence-producing"; both terms
refer to the persistent and repetitive intake of psychoactive substances
despite evidence of harm and a desire to quit. Some scientific
organizations have replaced the term "addictive" with "dependence-
producing" to shift the focus to dependent patterns of behavior and
away from the moral and social issues associated with addiction. Both
terms are equally relevant for purposes of understanding the drug
effects of nicotine.
II.
Introduction and Nature of the Action
24. The diseases related to and caused by the smoking of cigarettes
have killed millions of Americans over the last several decades, and
the killing continues. In order to earn larger profits, cigarette
manufacturers and their allied interests have chosen to ignore and
actively suppress the truth concerning the hazards of smoking
cigarettes. As a direct result, Kansas citizens entitled to Medicaid
benefits and other medical, pharmaceutical and health care assistance
from the State through a variety of State-funded programs have
contracted smoking-related diseases including, without limitation,
cancer, emphysema, and heart disease. The care and treatment of these
Kansas citizens has placed a significant financial burden on the State
and its taxpayers. This fiscal burden on all of Kansas' citizens
rightfully should be borne by the Tobacco Companies and their allied
interests.
25. Under the Kansas Constitution and other laws of the State of
Kansas, including, among others, the Social Welfare Act, K.S.A. 39-
701, et seq., the State is responsible for the health, safety and welfare
of its citizens, and the Attorney General has the duty to protect the
interests of the general public. The State of Kansas, on the relation of
Attorney General Stovall, brings this action under State law for money
damages, civil penalties, declaratory and injunctive relief, indemnity,
restitution, and investigative fees and expenses. As set forth more
particularly below, the various Defendants, over a long period of time
and continuing to the present day, conspired to deceive the State and
its citizens about the addictive properties of nicotine and the full extent
of the health risks of smoking. Every year in Kansas, several
thousand addicted smokers die from using Defendants' products
precisely as Defendants have designed and intended for those products
to be used. Through a well-organized campaign of fraud, lies,
intimidation, and deception, Defendants have avoided legal
responsibility for engineering, manufacturing and selling the most
deadly and harmful consumer product in history, while reaping
billions of dollars in profits.
26. In carrying out their conspiracy, the Defendants have committed
numerous fraudulent and unlawful acts, including, but not limited, to
the following:
a. Publicly undertaking, as a "paramount" special responsibility, the
duty of researching and disclosing to public health authorities and the
public at large, including the State of Kansas, the full extent of the
health risks of cigarette smoking, but then suppressing, concealing,
distorting, and lying about the state and extent of their true knowledge
of those risks;
b. Creating, controlling, directing, and/or funding fraudulent "rump"
or "front" organizations, such as the Tobacco Industry Research
Council (later known as the Council for Tobacco Research, a
Defendant herein), which was held out to the public as an independent
research organization, but which was in fact secretly controlled by
lawyers and public relations firms, to prevent the public from learning
what the Defendants knew about the health risks of smoking;
c. Secretly destroying, concealing, and otherwise spoliating and
shipping overseas incriminating evidence of industry testing and
research on the health risks of cigarette smoking and the addictive
nature of nicotine, shutting down laboratories on short notice and
making personal threats against their own scientists who tried to
publish research revealing what the industry actually knew about the
risks of smoking, and asserting false claims of attorney-client
privilege and attorney work product privilege in order to conceal their
own damaging scientific research;
d. Engaging in unconscionable and deceptive acts and practices by,
among other things, jointly sponsoring false, deceptive, and
misleading advertising, promotional and public relations campaigns
intended to confuse and create doubt among governmental entities,
including the State of Kansas, and the public about the health risks of
cigarette smoking;
e. Jointly and collectively making false, misleading, and sham
representations to Congress, other governmental entices, including the
State of Kansas, and the public regarding the health risks of cigarette
smoking, the addictive nature of nicotine, and the manipulation of
nicotine levels in cigarettes, in order to inundate Congress and other
federal and State entities with false and misleading information on the
true risks of cigarette smoking, and with the intent to defraud,
knowing that the State and others would reasonably rely on their
representations;
f. Conspiring to use monopoly power, and using that power to
suppress research into the health effects of smoking and to halt
research, development, marketing and sales of so-called "safer"
cigarettes that caused less biological activity in smokers; and
g. Engaging in unfair trade practices by targeting, marketing and
advertising efforts to promote illegal sales of cigarettes to minors, and
developing products and deceptive advertising campaigns.
27. As a direct and foreseeable result of these and other wrongful
actions by the Defendants, consumers and the State of Kansas have
suffered enormous damages. Over a period of many years, the State
has paid hundreds of millions of dollars in medical assistance for
smoking-related health care costs which would not have been incurred
absent Defendants' misconduct. Defendants created an ongoing public
health crisis of unrivaled proportions, all the while knowing and
appreciating full well that the State of Kansas would be required to
pay for the health care costs of its indigent and needy citizens who
suffer from smoking-related illnesses and disease processes. Under
time-honored principles of equity, the State of Kansas is entitled to
restitution and indemnity for the medical assistance funds it has paid,
because under the circumstances, it would be unjust and
unconscionable for the Defendants to retain the benefits the State of
Kansas conferred upon them or to profit in any way from their illegal
course of conduct. Further, by intentionally and/or willfully
concealing the risks and hazards of smoking, Defendants consciously
misled, prevented and delayed the State of Kansas from taking such
steps as necessary to avoid certain health care costs directly
attributable to smoking-related illnesses and disease processes.
28. The Defendant Tobacco Companies are a cartel that controls nearly
100% of the market for cigarettes in the United States. Their
longstanding conspiracy to mislead the public about the harmful and
addictive effects of cigarette smoking has placed the Defendants
among the most profitable industries in the world. The breadth and
boldness of the conspiracy recently was displayed before Congress
when, in April of 1994, the Chief Executive Officers of the leading
cigarette manufacturers testified under oath that they do not believe
that smoking causes death or that smoking is addictive. In truth, the
Defendants themselves have known for much longer than the scientific
community and public health authorities, including those in the State
of Kansas, that cigarettes are both addictive and deadly.
29. Despite representations to the contrary, Defendant manufacturers
carefully calibrate, control and manipulate nicotine in cigarettes so that
beginning smokers and others will become addicted to nicotine and
develop a physical and psychological dependency that can be satisfied
only by cigarette smoking. As a direct result of Defendants'
knowledge of and methods chosen to manufacture cigarettes, long-
term smokers find it extremely difficult and painful, and in many cases
impossible, to withdraw from their physical dependency on nicotine.
30. With full knowledge that they are selling an addictive and deadly
product, Defendants deliberately and willfully advertise, promote and
market cigarettes in such a way as to target promising markets of new
smokers, such as minors. Every day, according to reputable studies,
3,000 American youths are seduced by Defendants' unconscionable,
unfair and misleading advertising and marketing ploys and start
smoking, each then becoming a potential addict and life-long profit
center for the Defendants.
31. Despite the particularly harmful health consequences of smoking
for women, Defendants target advertising to this segment of the
population. For women, smoking reduces fertility, increases the rate
of miscarriages and stillbirths, retards uterine fetal growth and results
in lower birth weights in infants. Yet Defendants have targeted and
continue to target young women with advertising campaigns designed
to appeal psychologically to this group of potential smokers.
32. These outrageous marketing strategies further the conspiracy to
distort the truth about cigarette smoking. The net effect of Defendants'
unlawful, deceptive, and unconscionable conduct, over the past
several decades, has been to convey the message that intensive and
thorough scientific and medical research has uncovered no reliable
evidence about the real health effects of smoking. As described by one
industry representative, Defendants' campaign of deception has been a
"brilliantly conceived and executed" strategy to "creat[e] doubt about
the health charge without actually denying it." Defendants knew that if
smokers fully appreciated the risks of addiction and death, many
would never have started smoking or would have quit, and
Defendants would have lost the enormous profits they accumulated by
shifting the costs of their conduct onto the State of Kansas and others.
33. Armed with coffers full from the highly profitable sale of an
addictive drug, the Defendants have successfully fended off legal
attacks with a litigation strategy of expense, attrition and delay.
According to an attorney for Defendant R.J. Reynolds Tobacco
Company, "[T]he aggressive posture we have taken regarding
depositions and discovery in general continues to make these cases
extremely burdensome and expensive for plaintiffs' lawyers,
particularly sole practitioners. To paraphrase General Patton, the way
we won these cases was not by spending all of [Reynolds's] money,
but by making that other [expletive] spend all his. "
34. Defendants' conduct has generated a terrible human tragedy.
Cigarette smoking is the leading cause of premature death in the
United States. According to the federal Centers for Disease Control
and Prevention, each year cigarette smoking kills more than 400,000
Americans, exceeding the combined deaths caused by automobile
accidents, AIDS, alcohol abuse, use of illegal drugs, homicide,
suicide, and fires. Smoking-related illnesses account for one of every
five deaths each year in the United States.
35. Cigarette smoking causes, among other serious illnesses, cancer,
pulmonary diseases, and coronary heart disease:
a. Cancer -- Many chemicals in cigarette smoke have been determined
to be carcinogenic. Cigarette smoking is responsible for at least 30%
of all deaths from cancer. Cigarette smoking causes more than 85% of
all lung cancer, which has now surpassed breast cancer as the primary
cause of death from cancer among women. Smoking is linked to
cancers of the mouth, larynx, esophagus, stomach, pancreas, uterus,
cervix, kidney and colon, among others.
b. Pulmonary Disease -- Smoking is the cause of more than 80% of
deaths from pulmonary diseases such as emphysema and bronchitis.
These diseases have a particularly profound social impact because of
the prolonged and extended suffering and disability of their victims.
c. Heart Disease - Cigarette smoking is one of the major independent
causes of coronary heart disease. Smoking is also responsible for
thousands of deaths from cardiovascular disease, including stroke,
heart attack, peripheral vascular disease and aortic aneurysm.
36. The impact of cigarette smoking on the nation is staggering. In
May of 1993, the Office of Technology Assessment advised the
United States Congress that in 1990 smoking related illnesses cost
United States taxpayers a total of approximately $68 billion, broken
down as follows: $20.8 billion in direct costs; $6.9 billion in indirect
costs for morbidity; $40.3 billion indirect cost for mortality.
37. The State of Kansas greatly bears the horrible human and financial
costs of cigarette smoking. Thousands of Kansas citizens die each
year from smoking-related diseases, and the costs related to smoking
in Kansas are in the hundreds of millions of dollars each year.
38. The State of Kansas seeks monetary damages, civil penalties,
declaratory and injunctive relief, restitution, indemnity, investigative
fees, costs, and other appropriate relief for the Defendants' wrongful
conduct as described and alleged in this Petition. The State also seeks
injunctive relief to require the Defendants to cease marketing tobacco
products to children, seeks an Order requiring the Defendants to
disclose their research on smoking, addiction and health, and
requiring the Defendants to fund a remedial public education campaign
on the true health consequences of smoking, and requiring the
Defendants to fund smoking cessation programs for nicotine
dependent smokers who look to the State for provision of their health
care.
III.
Jurisdiction and Venue
39. This Court has jurisdiction over the subject matter of this action
pursuant to, among other authority, the provisions of K.S.A. 50-101
et seq. (the Kansas Antitrust Act) and the Kansas Consumer
Protection Act. The Court has personal jurisdiction over the
nonresident Defendants pursuant to, among other authority, the
provisions of K.S.A. 60-308(b).
40. Venue is proper in the District Court of Shawnee County, Kansas,
pursuant to, among other authority, the Kansas Antitrust Act and the
Kansas Consumer Protection Act.
IV.
Relevant Market
41. For the purposes of this action, the sale of cigarettes is the relevant
product market. The relevant geographic markets are the United States
and the State of Kansas.
V.
Common Factual Allegations
42. Senior tobacco industry executives have been quoted as
acknowledging the addictive nature of cigarettes. F. Ross Johnson,
former CEO of R.J. Reynolds was quoted in the October 6, 1994
edition of The Wall Street Journal as saying: "Of course it's addictive.
That's why you smoke the stuff." In a 1963 document which was
revealed in Congressional hearings in 1994, Addison Yeaman, Brown
& Williamson's General Counsel, wrote: "We are, then, in the
business of selling nicotine, an addictive drug...."
43. On April 14, 1994, each of the chief executives of The Tobacco
Companies swore by his oath that he believed nicotine is not
addictive. Testifying before the House Subcommittee on Health and
the Environment of the Committee on Energy and Commerce, chaired
by Congressman Henry Waxman, these executives misrepresented
their companies' knowledge about the health risks of smoking,
nicotine addiction, and nicotine manipulation in the cigarette
manufacturing process. William I. Campbell, then President and CEO
of Philip Morris stated that "Philip Morris does not manipulate nor
independently control the level of nicotine in our products."; that
"Cigarette smoking is not addictive."; and "Philip Morris research
does not establish that smoking is addictive." James W. Johnston,
R.J. Reynolds' CEO said that "Smoking is no more addictive than
coffee, tea or Twinkies." Andrew Tisch, then CEO of Lorillard,
asserted that smoking does not cause death: "We have looked at the
data and the data that we have been able to see has all been statistical
data that has not convinced me that smoking causes death."
44. In fact, research conducted by Philip Morris scientists - which
Philip Morris and other Defendants attempted to suppress -- has
demonstrated, in the scientists' own words, that nicotine is addictive
"on a level comparable to cocaine." High-ranking executives in the
tobacco industry have privately acknowledged, since the early 1960s,
that nicotine is an addictive drug. For example, Addison Yeaman,
General Counsel at Brown & Williamson, wrote in an internal
memorandum in 1963: "Moreover, nicotine is addictive. We are, then,
in the business of selling nicotine, an addictive drug effective in the
release of stress mechanisms." And in 1962, the Scientific Advisor to
the Board of Directors of British American Tobacco Company
("BATCO"), Brown & Williamson's parent company, stated that
"smoking is a habit of addiction" and that "[n]icotine is not only a very
fine drug, but the technique of administration by smoking has
considerable psychological advantages...." He subsequently described
Brown & Williamson as being "in the nicotine rather than the tobacco
industry."
45. The Tobacco Company executives' false Congressional testimony
about nicotine is but the most recent episode in the industry's
campaign, spanning 50 years, to sow confusion and misinformation
about the true health effects of smoking. As described in various
internal memoranda of tobacco industry executives, the scheme has
been "a brilliantly conceived and executed" strategy to "creat[e] doubt
about the health charge without actually denying it."
A. The Tobacco Industry Conspiracy to Deceive the Public About
Disease and Death
46. Although tobacco in various forms has been consumed by
Americans for many, many years, it was not until the 19th century that
an easily inhalable tobacco product, the cigarette, became widely
popular. Cigarette smoking increased dramatically in the first half of
the 20th century. As early as 1946, tobacco company chemists
themselves reported concern for the health of smokers. A 1946 letter
from a Lorillard chemist to its manufacturing committee states:
"Certain scientists and medical authorities have claimed for many
years that the use of tobacco contributes to cancer development in
susceptible people. Just enough evidence has been presented to justify
the possibility of such a presumption." Neither this letter nor the
information it contained was ever voluntarily released to the public.
1. Claiming Cigarette's Are Healthful
47. Industry spokesmen referred to these and similar reports as "the
health scare," and throughout the 1930s through the 1950s, countered
with express advertising claims and warranties as to the healthfulness
of their products. These claims were knowingly and/or recklessly
false, misleading, deceptive, unconscionable, and/or fraudulent.
Examples of these health warranties appear in the following
paragraphs 48 through 54.
48. Old Gold reacted to early medical studies with the slogan: "If
pleasure's your aim, not medical claims..." and made claims such as
"Old Gold -- Not a cough in a Carload."
49. R.J. Reynolds claimed that there was "Not a single case of throat
irritation due to smoking Camels."
50. Philip Morris brand was held out as "The Throat-tested cigarette"
on the basis of supposed studies showing that Philip Morris brand
cigarettes were less irritating. An ad by the company in a 1943 issue
of the National Medical Journal read: "'Don't smoke' is advice hard
for patients to swallow. May we suggest instead 'Smoke Philip
Morris?' Tests showed three out of every four cases of smokers'
cough cleared on changing to Philip Morris. Why not observe the
results yourself?"
51. In 1942, Brown & Williamson claimed that Kools would keep the
head clear and/or give extra protection against colds.
52. In 1952, Liggett & Myers widely publicized the "results" of tests
showing that "smoking Chesterfields would have no adverse effects
on the throat, sinuses or affected organs." The tests were conducted
by Arthur D. Little, Inc. for advertising purposes and were designed
to have no real scientific value. These ads ran, among other places, on
the nationally popular Arthur Godfrey radio and television show.
Arthur Godfrey subsequently contracted lung cancer caused by
smoking cigarettes.
53. Ads from the 1930s and 1940s often carried wide-ranging medical
claims that placed cigarette-touting physicians in the company of
endorsers such as Santa Claus ("Luckies are easy on my throat"),
movie stars, sports heroes, and circus stars. Some companies hired
attractive women to deliver cigarette samples to physicians and the
patients in their waiting rooms.
54. In the New York State Journal of Medicine, Chesterfield ads
began running in 1933 and often carried claims such as "Just as pure
as the water you drink...and practically untouched by human hands."
55. During the 1950s, Defendants attempted to counter the "health
scare" with campaigns like "The Filter Derby" and "Tar Wars,"
making false and fraudulent warranties of health claims based on tar
and nicotine content.
56. Defendants sponsored cigarette ads in medical journals such as the
Journal of the American Medical Association ("JAMA") from the
1930s through the 1950s. After the appearance of landmark studies
such as the 1952 JAMA article on smoking and bronchial carcinoma
by Alton Ocshner, M.D., JAMA ceased running cigarette ads.
2. The Conspiracy is Born to Counter "The Big Scare"
57. The industry conspiracy became much more sophisticated and
began in earnest in the 1950s, when the Tobacco Companies were
confronted with the publication of several scientific studies which
sounded grave warnings on the health hazards of cigarettes. The
widespread reporting of these studies caused what Tobacco Company
officials later called the "Big Scare."
58. Confronted with the studies, the presidents of the leading Tobacco
Companies met at an extraordinary gathering in the Plaza Hotel in
New York City on December 15, 1953. Defendant Hill & Knowlton,
a public relations agency, coordinated the meeting and later prepared a
memorandum summarizing the discussions of that day. According to
the Hill & Knowlton memorandum:
a. The companies had not met together since two previous antitrust
decrees had prohibited "many group activities." However the
companies viewed the current problem "as being extremely serious
and worth of drastic action."
b. Another indication of the seriousness of the problem was "that
salesmen in the industry are frantically alarmed and that the decline in
tobacco stocks on the stock exchange market has caused grave
concern...."
c. The situation was viewed entirely in terms of a public relations
problem, as opposed to a public health concern. The industry leaders
"feel that the problem is one of promoting cigarettes and protecting
them from these and other attacks that may be expected in the future"
and that the industry "should sponsor a public relations campaign
which is positive in nature and is entirely 'pro-cigarettes.'"
d. All of the leading manufacturers, except Liggett, agreed to "go
along" with the public relations strategy. Liggett decided not to
participate at that time "because that company feels that the proper
procedure is to ignore the whole controversy."
e. The group discussed forming an association "specifically charged
with the public relations function."
f. Hill & Knowlton was to play a central role in the industry
association. "The current plans are for Hill and Knowlton to serve as
the operating agency of the companies, hiring all the staff and
disbursing all funds."
59. Thus, the Tobacco Industry Research Committee ("TIRC"),
eventually renamed as The Council for Tobacco Research ("CTR"),
was conceived and born with five of the largest six cigarette
manufacturers as original members. Liggett finally joined in 1964, in
response to the Surgeon General's first report on smoking and health.
60. Nine days after the December 15, 1953 meeting, Hill and
Knowlton presented a detailed recommendation to the cigarette
manufacturers and others. The recommendation recognized the
importance of gaining the public trust, and avoiding the appearance of
bias, if the "pro-cigarette" industry strategy was to be successful.
According to the memorandum:
a. "[T]he grave nature of a number of recently highly publicized
research reports on the effects of cigarette smoking... have confronted
the industry with a serious problem of public relations."
b. "It is important that the industry do nothing to appear in the light of
being callous to considerations of health or of belittling medical
research which goes against cigarettes."
c. "The situation is one of extreme delicacy. There is much at stake
and the industry group, in moving into the field of public relations,
needs to exercise great care not to add fuel to the flames."
3. The "Frank Statement to Cigarette Smokers" -a Scheme to Defraud
Consumers
61. The cigarette industry announced the formation of TIRC on
January 4, 1954, with newspaper advertisements placed in virtually
every city with a population of 50,000 or more, reaching a circulation
of more than 43 million Americans. The advertisement was captioned
"A Frank Statement to Cigarette Smokers" and was run under the
auspices of TIRC with, among others, five of the largest six
manufacturers -- American Tobacco Co., R.J. Reynolds, Philip
Morris, U.S. Tobacco Co., Lorillard, and Brown & Williamson
Tobacco Corporation -- listed by name. The advertisement promised
that Defendants would undertake the responsibility of learning and
disclosing the facts about smoking.
RECENT REPORTS on experiments with mice have given wide
publicity to a theory that cigarette smoking is in some way linked with
lung cancer in human beings.
Although conducted by doctors of professional standing, these
experiments are not regarded as conclusive in the field of cancer
research. However, we do not believe that any serious medical
research, even though its results are inconclusive, should be
disregarded or lightly dismissed.
At the same time, we feel it is in the public interest to call attention to
the fact that eminent doctors and research scientists have publicly
questioned the claimed significance of these experiments.
Distinguished authorities point out:
1. That medical research of recent years indicates many possible
causes of lung cancer.
2. That there is no agreement among the authorities regarding what the
cause is.
3. That there is no proof that cigarette smoking is one of the causes.
4. That statistics purporting to link cigarette smoking with the disease
could apply with equal force to any one of many other aspects of
modern life. Indeed the validity of the statistics themselves is
questioned by numerous scientists.
We accept an interest in people's health as a basic responsibility,
paramount to every other consideration in our business.
We believe the products we make are not injurious to health.
We always have and always will cooperate closely with those whose
task it is to safeguard the public health.
For more than 300 years tobacco has given solace, relaxation, and
enjoyment to mankind. At one time or another during those years
critics have held it responsible for practically every disease of the
human body. One by one these charges have been abandoned for lack
of evidence.
Regardless of the record of the past, the fact that cigarette smoking
today should even be suspected as a cause of a serious disease is a
matter of deep concern to us.
Many people have asked us what we are doing to meet the public's
concern aroused by the recent reports. Here is the answer:
1. We are pledging aid and assistance to the research effort into all
phases of tobacco use and health. This joint financial aid will of
course be in addition to what is already being contributed by
individual companies.
2. For this purpose we are establishing a joint industry group
consisting initially of the undersigned. This group will be known as
TOBACCO INDUSTRY RESEARCH COMMITTEE.
3. In charge of the research activities of the Committee will be a
scientist of unimpeachable integrity and national repute. In addition
there will be an Advisory Board of scientists disinterested in the
cigarette industry. A group of distinguished men from medicine,
science, and education will be invited to serve on this Board. These
scientists will advise the Committee on its research activities.
This statement is being issued because we believe the people are
entitled to know where we stand on this matter and what we intend to
do about it.
62. In this advertisement, the participating Defendant Tobacco
Companies recognized their "special responsibility" to the public, and
promised to learn the facts about smoking and health. The
participating Defendant Tobacco Companies promised to sponsor
independent research on the subject, claiming they would make health
a basic responsibility, paramount to any other consideration in their
business. The participating Defendant Tobacco Companies also
promised to cooperate closely with public health officials. At the time
these promises were made, Defendants had no intent to honor their
promises. They have repeatedly breached their promises thus made to
the public, including their promises made to the public health officials
and citizens of Kansas.
4. "Scientific Research" as a Public Relations Front: Control of TIRC
by Hill & Knowlton
63. As had been proposed at the December 15, 1953 meeting,
Defendant Tobacco Companies (without Liggett), through their agent
Defendant Hill & Knowlton, operated and effectively controlled
TIRC.
64. TIRC was physically established in the Empire State Building,
one floor below the Hill & Knowlton offices. Internal documents
confirm that Hill & Knowlton, and not independent scientists, actually
ran TIRC. A "highly confidential" internal memo reported:
"Since the [TIRC] had no headquarters and no staff, Hill and
Knowlton, Inc. was asked to provide a working staff and temporary
office space. As a first organizational step, public relations counsel
assigned one of its experienced executives, W.T. Hoyt, to serve as
account executive and handle as one of his functions the duties of
executive secretary for the [TIRC]"
65.In 1954, 35 staff members of Hill and Knowlton worked full or
part time for TIRC.In that year, TIRC spent $477,955.00 on
payments to Hill and Knowlton, over 5096 of TIRC's entire budget.
66. After lulling the public into a false sense of security concerning
smoking and health, the TIRC continued to act as a front for tobacco
industry interests. Despite the initial public statements and posturing,
and the repeated assertions that they were committed to full disclosure
and vitally concerned, the TIRC secretly failed to make the public
health a primary concern. The Tobacco Trade Associations acted at the
direction of the Tobacco Companies and the Tobacco Consultants to
protect tobacco industry profits, and did not act to protect the public
health. In fact, there was a coordinated, industry-wide strategy
designed actively to mislead and confuse the public about the true
dangers associated with smoking cigarettes. Rather than work for the
good of the public health as it had promised, and sponsor independent
research, the Tobacco Companies and Tobacco Consultants, acting
through the Tobacco Trade Associations, refuted, undermined,
distorted, concealed and neutralized information coming from the
scientific and medical community.
67. By the spring of 1955, the self-defense strategy recommended by
Hill and Knowlton and implemented by the Defendants through the
"Frank Statement" was largely successful. Hill and Knowlton
reported to TIRC:
a. "progress has been made"... "The first big scare continues on the
wane."
b. The research program of the [TIRC] has won wide acceptance in
the scientific world as a sincere, valuable and scientific effort."
c. "Positive stories are on the ascendancy."
5. The True Nature of the CTR
68. Since its inception, the CTR has functioned as a remarkably
effective vehicle to perpetuate the deception that the health risks of
smoking and nicotine addiction have never been proven. The industry
has congratulated itself on a brilliantly conceived and executed strategy
to create doubt about the charge that cigarette smoking is deleterious to
health without actually denying it. A 1962 memo stated that the
industry had handled the "Big Scare" effectively, by treating the public
health threat as a public relations problem that was solved for the self-
preservation of the industry's image and profit. One Defendant's
executive called the CTR the best, cheapest insurance the tobacco
industry can buy, noting that with it, Defendants would have to invent
CTR or would be dead.
69. In 1993, a former 24-year employee of CTR confirmed publicly
that the joint industry research efforts were not objective: "When CTR
researchers found out that cigarettes were bad and it was better not to
smoke, we didn't publicize that. The CTR is just a lobbying thing. We
were lobbying for cigarettes."
6. The Lawyers' Control of Scientific Research
70. The Defendants have used lawyers and fraudulent, deceptive,
unconscionable, and false claims of Attorney/Client privilege and
Work Product to insulate CTR-funded research projects from
disclosure to the public and to government officials. This conduct
demonstrates the falsity of the industry representations jointly to fund
objective research and to report the results of that research to the
public.
71. CTR used the term "Special Projects" to mean a project that
carried a risk of a negative result that might have to be suppressed.
"Special Projects" were selected and monitored by Tobacco Attorneys
to prevent disclosure. One Philip Morris official characterized CTR as
a "front" for performing "special projects."
72. Notes prepared at a 1981 meeting of the cigarette industry's
Committee of General Counsel state: "When we started the CTR
Special Projects, the idea was that the scientific director of CTR would
review a project. If he liked it, it was a CTR special project. If he did
not like it, then it became a lawyers' special project.... We were afraid
of discovery for FTC and Aviado, we wanted to protect it under the
lawyers. We did not want it out in the open."
73. The sole purpose of this "Special Projects" division within CTR
was to conceal research that was harmful to the tobacco industry and
to promote and develop research and expert witnesses needed for the
defense of tort litigation. Incriminating reports and documents
contained within this division were passed through the Tobacco
Attorneys and are now claimed by Defendants to be privileged.
74. CTR-sponsored research projects were directed away from
research that might add to the evidence against smoking. When CTR-
sponsored research did produce unfavorable results, however, the
information was distorted or simply suppressed. For example, Dr.
Freddy Homburger, a researcher in Cambridge, Massachusetts,
undertook a study of smoke exposure on hamsters. According to Dr.
Homburger, he received a grant from CTR which was changed half-
way through the study to a contract "so they could control publication
-- they were quite open about that." Dr. Homburger has testified that
when the study was completed in 1974, the Scientific Director of CTR
and a CTR lawyer "didn't want us to call anything cancer" and that
they threatened Dr. Homburger with "never get[ting] a penny more" if
his paper was published without deleting the word cancer.
75. An internal CTR document describes how Dr. Homburger
attempted to call a press conference about the incident and how CTR
stopped it: "He... was to tell the press that the tobacco industry was
attempting to suppress important scientific information about the
harmful effects of smoking. He was going to point specifically at
CTR. I arranged later that evening for it to be canceled. Homburger
was given a cordial welcome and nicely hastened out the door. P.S. I
doubt if you or Tom will want to retain this note."
76. Not content with the holding strategy employed by the TIRC and
the CTR, Defendants advocated a more offensive role through their
lobbying arm, the Tobacco Institute. This tobacco industry-supported
group actively seeks to increase doubt about the negative health effects
of smoking by suggesting that there are alternative explanations to the
data. One "theory" detailed how individual genetic makeups
predisposed individuals to illnesses. Another, the "multi-factorial
hypothesis," asserted that multiple factors should be blamed, i.e.,
food additives, viruses, occupational hazards, air pollution or stress,
for causing cancer. The tobacco industry financed, supported and
encouraged the manufacture of fraudulent science.
7. Tobacco Industry Concealment and Disinformation
77. On February 6, 1992, United States District Court Judge H. Lee
Sarokin for the District of New Jersey issued an opinion in Haines v.
Liggett Group, Inc., Civ. Action 84-678. After reviewing 1500
documents in camera, Judge Sarokin noted that "In 1954, the tobacco
industry promised to disseminate the results of industry-sponsored,
independent scientific research for the purpose of answering the
question: 'Does cigarette smoking cause illness?' To fulfill its
promise, the tobacco industry proffered the allegedly 'independent'
research organization, the Council for Tobacco Research (the CTR),
which purportedly would examine the risks of smoking and report its
findings to the public." After his review of the withheld documents,
Judge Sarokin concluded that Defendants had intentionally breached
their promises to the public:
"Despite the industry's promise to engage independent researchers to
explore the dangers of cigarette smoking and to publicize their
findings the evidence clearly suggests the research was not
independent; that potentially adverse results were shielded under the
caption of 'special projects'; that the attorney-client privilege was
intentionally employed to guard against such unwanted disclosure; and
that the promise of full disclosure was never meant to be honored, and
never was."
78. As a result of this finding, Judge Sarokin went on to note that
Defendants' actions constituted a fraud:
"A jury might reasonably conclude that the industry's announcement
of proposed independent research into the dangers of smoking and its
promise to disclose its findings was nothing but a public relations ploy
-- a fraud -- to deflect the growing evidence against the industry, to
encourage smokers to continue and non-smokers to begin, and to
reassure the public that adverse information would be disclosed."
8. Continued False Promises to the Public
79. Using CTR as a "front," Defendants pursued a public
disinformation strategy to confuse and mislead public health
authorities and the public about the true health risks of cigarette
smoking.
80. Defendants created a publication called Tobacco and Health (later,
Tobacco and Health Research), distributed it to the press, doctors, and
health officials, to disseminate false information and generate
confusion over the causal connection between cigarette smoking and
disease. The "Criteria For Selection" of articles for publication
included an example of "a report in which smoking-associated
diseases are questioned. "
81. The deceptions of the 1954 "Frank Statement to Cigarette
Smokers" were renewed and repeated by the industry. R.J. Reynolds
Chairman Bowman Gray told Congress in 1964: "If it is proven that
cigarettes are harmful, we want to do something about it regardless of
what somebody else tells us to do. And we should do our level best.
It's only human."
82. The January 15, 1968 issue of True Magazine contained an article
written by Stanley Frank called, "To Smoke or Not to Smoke -- That
is Still the Question." The article dismissed the evidence against
smoking as "inconclusive and inaccurate" and claimed that "[s]tatistics
alone link cigarettes with lung cancer... it is not accepted as scientific
proof of the cause and effect." A few months later, a similar but
shorter article appeared in the National Enquirer entitled "Cigarette
Cancer Link is Bunk" written by "Charles Golden" (a fictitious name
commonly used by the Enquirer). The real author was Stanley Frank.
Two million reprints of the True Magazine article were distributed to
physicians, scientists, journalists, government officials, and other
opinion leaders with a small card which stated, "As a leader in your
profession and community, you will be interested in reading this story
from the January issue of True Magazine about one of today's
controversial issues." The cost for this was paid by Brown and
Williamson, Philip Morris and R.J. Reynolds. It was subsequently
disclosed that author Frank had been paid $500 to write the article by
Joseph Field, a public relations professor working for Brown and
Williamson. Brown and Williamson reimbursed Field for that amount.
83. In 1970, the Tobacco Institute ran an advertisement captioned "A
Statement about Tobacco and Health," which stated:
a. "We recognize that we have a special responsibility to the public --
to help scientists determine the facts about tobacco and health, and
about certain diseases that have been associated with tobacco use."
b. "We accepted this responsibility in 1954 by establishing the
Tobacco Industry Research Committee, which provides research
grants to independent scientists. We pledge continued support of this
program of research until all the facts are known."
c. "Scientific advisors inform us that until much more is known about
such diseases as lung cancer, medical science probably will not be
able to determine whether tobacco or any other single factor plays a
causative role -- or whether such a role might be direct or indirect,
incidental or important."
d. "We shall continue all possible efforts to bring the facts to light."
84. Also, in 1970, the Tobacco Institute ran an advertisement
captioned, "The question about smoking and health is still a question."
In this advertisement, the Tobacco Institute stated:
a. "[A] major portion of this scientific inquiry has been financed by
the people who know the most about cigarettes and have a great desire
to learn the truth... the tobacco industry.
b. "[T]he industry has committed itself to this task in the most
objective and scientific way possible."
c. "In the interest of absolute objectivity, the tobacco industry has
supported totally independent research efforts with completely
nonrestrictive funding."
d. "Completely autonomous, CTR's research is directed by a board of
ten scientists and physicians.... This board has full authority and
responsibility for policy, development and direction of the research
effort."
e. "The findings are not secret."
f. "From the beginning, the tobacco industry has believed that the
American people deserve objective, scientific answers. "
85. Again, in 1970, the Tobacco Institute stated, "The Tobacco
Institute believes that the American public is entitled to complete,
authenticated information about cigarette smoking and health." The
Tobacco Institute further stated that, "The tobacco industry recognizes
and accepts a responsibility to promote the progress of independent
scientific research in the field of tobacco and health."
B. The Tobacco Industry's Knowledge That Smoking Kills
86. In the years following the 1954 "Frank Statement," and
continuing to the present, Defendants have repeatedly acted in breach
of their assumed duty to report objective facts on smoking and health.
As evidence mounted, both through industry research and truly
independent studies, that cigarette smoking causes cancer and other
diseases, Defendants continued publicly to represent that nothing was
proven against smoking. Internal documents show that the truth was
very different. Defendants knew and acknowledged internally the
veracity of scientific evidence of the health hazards of smoking, and at
the same time suppressed such evidence where they could, and
attacked it when it did appear publicly.
87. As early as 1946, Lorillard chemist H.E. Parmele, who later
became Vice President of Research and a member of Lorillard's Board
of Directors, wrote to his company's manufacturing committee:
"Certain scientists and medical authorities have claimed for many
years that the use of tobacco contributes to cancer development in
susceptible people. Just enough evidence has been presented to justify
the possibility of such a presumption."
88. A 1956 memorandum from the Vice President of Philip Morris'
Research and Development Department to top executives at the
company regarding the advantages of "ventilated cigarettes" stated
that: "Decreased carbon monoxide and nicotine are related to decreased
harm to the circulatory system as a result of smoking.... Decreased
irritation is desirable..as a partial elimination of a potential cancer
hazard."
89. A 1958 memorandum sent to the Vice President of Research at
Philip Morris, who later became a member of its Board of Directors,
from a company researcher stated "the evidence...is building up that
heavy cigarette smoking contributes to lung cancer either alone or in
association with physical and physiological factors...."
90. A 1961 document presented to the Philip Morris research and
Development Committee by the company's Vice President of Research
and Development included a section entitled ""Reduction of
Carcinogens in Smoke." The document stated, in part: "To achieve
this objective will require a major research effort, because carcinogens
are found in practically every class of compounds in smoke. This fact
prohibits complete solution of the problem by eliminating one or two
classes of compounds. The best we hope for is to reduce a particularly
bad class, i.e., the polynuclear hydrocarbons, or phenols.... Flavor
substances and carcinogenic substances come from the same classes,
in many instances."
91. A 1963 memorandum to Philip Morris' President and CEO from
the company's Vice President of Research describes a number of
classes of compounds in cigarette smoke which are "known
carcinogens." The document goes on to describe the link between
smoking and bronchitis and emphysema. "Irritation problems are now
receiving greater attention because of the general medical belief that
irritation leads to chronic bronchitis and emphysema. These are
serious diseases involving millions of people. Emphysema is often
fatal either directly or through other respiratory complications. A
number of experts have predicted that the cigarette industry ultimately
may be in greater trouble in this area than in the lung cancer field. "
92. Brown & Williamson and its parent company, British American
Tobacco Company, Ltd., researched the health effects of nicotine and
were aware early on, as reported at a B.A.T. Group Research
Conference in November 1970, that "nicotine my be implicated in the
aetiology [cause] of cardiovascular disease...."
93. A 1961 "Confidential" memorandum from the consulting research
firm hired by Liggett to do research for the company states: "There are
biologically active materials present in cigarette tobacco. These are: a)
cancer causing; b) cancer promoting; c) poisonous; d) stimulating,
pleasurable, and flavorful."
94. A 1963 memorandum from the Liggett consulting research firm
states: "Basically, we accept the inference of a causal relationship
between the chemical properties of ingested tobacco smoke and the
development of carcinoma, which is suggested by the statistical
association shown in the studies of Doll and Hill, Horn, and Dorn
with some reservations and qualifications and even estimate by how
much the incidence of cancer may possibly be reduced if the
carcinogenic matter can be diminished, by a appropriate filter, by a
given percentage."
C. Suppressing the Truth About Cigarettes and Nicotine
95. Not only have Defendants failed to disclose the information they
repeatedly pledged to make public, they have, or the contrary, actively
conspired to suppress research and publication concerning the health
risks of cigarette smoking, and to misstate and distort published
research linking smoking to disease, even going so far as to make
personal threats against the researchers themselves. A CTR director's
claim that tobacco industry scientists could "freely publish what they
find as they choose" was a hollow deception.
1. The Gentlemen's Agreement and the Lawyers' Role in the
Conspiracy
96. The actions of Defendants in suppressing and misleading the
public as to the harmful effects of cigarettes stands in sharp contrast to
Defendant Lorillard's 1994 assertion to Congress that the data had still
not convinced its CEO that smoking causes death. The tobacco
industry long ago entered into a "gentlemen's agreement" to suppress
independent research on smoking and health. A 1968 internal Philip
Morris draft memo refers to this conspiratorial agreement: "We have
reason to believe that in spite of gentlemen's agreement from the
tobacco industry in previous years that at least some of the major
companies have been increasing biological studies within their own
facilities." This memo also acknowledged that cigarettes are
inextricably intertwined with the health field, stating, "Most Philip
Morris products, both tobacco and non- tobacco, are directly related to
the health field."
97. The industry believed that individual Tobacco Companies were
performing certain research on their own in addition to the joint
industry research. But the fundamental understanding and agreement
remained intact: any harmful information and activities would be
restrained, suppressed, and/or concealed. This secret agreement
included restraining, suppressing, and concealing research on the
health effects of smoking, including the addictive qualities of nicotine,
and restraining, concealing, and suppressing the research and
marketing of safer cigarettes.
98. The General Counsel of the major cigarette manufacturers,
through joint meetings to review and direct proposals for scientific
research for the entire industry, furthered the conspiracy of the
tobacco industry, including the Tobacco Attorneys and Tobacco
Consultants, to intentionally mislead and defraud the public about
smoking and health. For example, Defendants have attempted
wrongfully to create a privilege for various documents reflecting
scientific research that they wish to conceal by routing such
documents to their legal departments and law firms to support claims
that such materials are protected from disclosure by the
Attorney/Client or attorney Work Product privileges.
99. The Tobacco Attorneys have played a critical role in furthering the
conspiracy to suppress and conceal information about the adverse
health effects caused by the use of tobacco products. The Tobacco
Attorneys' strategy was to attempt to protect damaging tobacco-related
documents from disclosure under the Attorney/Client or Work Product
privileges regardless of whether such documents were prepared in
anticipation of litigation or represented confidential communications
made between lawyer and client for the purpose of rendering legal
advice. Lawyers routinely provided a number of non-legal services to
the Defendants such as deciding which CTR "special projects" should
receive funding, dispensing funding to the "scientist" involved in such
projects, and designing the scope and approach of the special project.
The Tobacco Attorneys also undertook to coordinate the Tobacco
Companies' CTR "special projects" subterfuge.
100. The Council for Tobacco Research holds itself out, and has been
held out by the Tobacco Companies and the Tobacco Attorneys, as a
research body sponsoring independent research. Tobacco Attorneys
used the TIRC, predecessor to the CTR, as an industry "shield." The
CTR has acted as a "front" for the Tobacco Companies' litigation and
public relations goals. The Tobacco Attorneys have been instrumental
in this deception.
101. In orchestrating the CTR deception, the Tobacco Attorneys
became deeply involved in the screening, selection, funding,
supervision and ultimate disposition of research projects, channeling
sensitive research into "special projects" and "special accounts." A
Tobacco Attorney quoted in a 1981 internal tobacco industry
document said: "When we started the CTR Special Projects, the idea
was that the scientific director of CTR would review a project. If he
liked it, it was a CTR special project. If he did not like it, then it
became a lawyers' special project."
102. As to research which was progressing "satisfactorily" -- that is
turning up no negative results -- the Tobacco Attorneys recommended
it receive additional funding. Research which was troubling, either in
its direction or in its results, was redirected by the Tobacco Attorneys
or terminated.
103. For example, in 1976, a Tobacco Attorney wrote to in-house
lawyers at the various Tobacco Companies that a study to measure
environmental tobacco smoke should be modified in such a way that
so that the study would yield more favorable results for the Tobacco
Companies' position. The study was subsequently modified to de-
emphasize the role of second-hand tobacco smoke relating to indoor
environmental quality.
104. A 1980 letter from a Tobacco Attorney to the various General
Counsel of the tobacco industry, recommends a grant to Dr. Domingo
Aviado. Although Shinn states that "[t]his would be a no-strings
attached grant and Dr. Aviado would be free to publish," the role of
Tobacco Attorneys in supervising and ultimately controlling Dr.
Aviado's research is clear: aWe would anticipate a brief report toward
the end of this year concerning the project. Providing the project is
progressing satisfactorily, I anticipate recommending a renewal for a
second year and, thereafter, with the same proviso, for a third year."
105. Indeed, "satisfactory" progress in research is always the
touchstone for the Tobacco Attorneys. A telling 1981 memorandum
between General Counsel J. Kendrick Wells and executive Ernest
Pepples of defendant Brown & Williamson tells of a visit by a
Tobacco Attorney to a researcher: "It was a cordial meeting and Tim
believes he has persuaded them to take a new thrust with their
research. The new thrust will have questionable value but no negative.
106. In addition, a May 19, 1981 letter from Ernest Pepples, Vice
President and General Counsel of Brown & Williamson, to a Tobacco
Attorney requests that the attorney evaluate the qualifications of
various scientists seeking to conduct scientific studies for Brown &
Williamson. The attorney responded by providing biographical
sketches of potential consultants including whether they previously
had taken scientific position favorable to the industry's position. He
also cooperated with Pepples' request in 1984 to transfer the funding
of some helpful research by a cooperative scientist from a CTR
account to a law firm project: "I do not think...that we should continue
burdening CTR with such programs, and instead suggest that they be
handled as law firm projects.
107. In 1972, a Tobacco Attorney wrote to Tobacco Company
officials that a potentially favorable study should be secretly funded by
the Tobacco Companies as a "non-CTR special project" in order to
make the study appear independent of the industry and thus heighten
its perception as unbiased and reliable.
108. Similarly, a Tobacco Attorney wrote a letter to the General
Counsel of the tobacco industry urging them to approve a grant to Dr.
Henry Rothschild, who was doing a study on genetic links to lung
cancer. Although CTR had rejected Dr. Rothschild's request to renew
his grant, the attorney urged funding on the ground that "[h]is
research has evolved to a point where his primary focus was on a
possible genetic factor rather than environmental or occupational
factors."
109. The breadth of the involvement of the Tobacco Attorneys in the
selection of research projects to be funded, including those funded by
and through CTR, is reflected in the excerpts from the following letter:
The Research Liaison Committee has not had a meeting since July
1976. I have had discussion with individual members of the
committee about calling a meeting. It has been suggested that the
views of the companies with respect to the future activities of this
committee should first be explored through the Committee of
Counsel.... We may want to discuss research in a larger context, i.e.,
what are the industry's present needs? This, of course, involves
consideration of the role of institutional type projects (tobacco, e.g.,
Harvard, and nontobacco, e.g., Washington University); the role of
CTR; and the need for specific areas of research with due regard for
the politics of science, the importance of developing witnesses and the
need for a responsive mechanism to meet unfounded claims made
about tobacco.
110. In fact, a Tobacco Attorney chaired the Research Liaison
Committee, a committee comprised of representatives of the major
manufacturers "to study the research programs funded by our
industry, both through CTR and independent projects that are brought
to us from time to time." This committee "directed its primary attention
to the question of how industry research should be recommended,
decided upon, and supervised in order to accomplish the objective of
an efficient and coordinated program which would best serve the
needs and objectives of the industry." In addition to Tobacco Attorney
involvement in the Research Liaison Committee, Tobacco Attorneys
also sat on the CTR Committee of Counsel and the CTR Ad Hoc
Committee.
111. In addition, the Tobacco Attorneys abused the Attorney-Client
privilege and Work Product protections in order to shield Special
Projects and special accounts documents and cover-up the CTR fraud
from the public and government regulators. For example, in notes of a
1981 CTR Committee of Counsel meeting, transmitted by Tobacco
Attorneys, an attorney is quoted as stating:
"With Speilberger, we were afraid of discovery for FTC and Aviado,
we wanted to protect it under the lawyers. We did not want it out in
the open."
112. The Tobacco Attorneys also participated in the suppression of
development of a "safer" cigarette. Attempts by the tobacco industry to
develop a "safer" cigarette inevitably required its researchers to engage
in discussions regarding which constituents of tobacco smoke cause
disease and how they might be eliminated. These discussions greatly
concerned the Tobacco Attorneys because they would lead to
statements constituting admissions that could be used against the
Tobacco industry.
113. A 1970 letter from a Tobacco Attorney to DeBaun Bryant,
General Counsel for defendant Brown & Williamson, citing to the
minutes of two research conferences, stated that:
A plaintiff would be greatly benefited by evidence which tended to
establish actual knowledge on the part of a defendant that smoking is
generally dangerous to health, that certain ingredients are dangerous
and should be removed, or that smoking causes a particular disease.
This would not only be evidence that would substantially prove a case
against the defendant company for compensatory damages, but could
be considered as evidence of willfulness or recklessness sufficient to
support a claim for punitive damages.
Hardy concludes that "employees in both companies should be
informed of the possible consequences of careless statements on this
subject." In short, the Tobacco Attorneys were arguing that the
necessary discussions for the development of a "safer" cigarette must
stop.
114. Likewise, in 1987, a Tobacco Attorney wrote a lengthy
memorandum in which he expressed his concern that defendant R.J.
Reynolds' announcement of a nonburning, "clean" cigarette "could
immediately and significantly increase [tobacco companies'] exposure
to liability for sales of conventional cigarettes." In introducing the
product, particularly right before the start of two key trials, the
attorney also questioned defendant R.J. Reynolds' commitment to
"joint defense efforts."
115. By becoming intimately involved in the funding and design of
these scientific studies, these Tobacco Attorneys conspired with the
Tobacco Companies and CTR by (1) clothing such studies in the
attorney-client or work product privilege in order to protect them from
disclosure if their results were unfavorable, and (2) by creating the
perception that CTR and the Tobacco Companies were fairly and
appropriately fulfilling their obligations and promises to the public that
they would, in a vigorous and unbiased manner investigate and report
to the public the link between their products and human disease.
116. In addition, Tobacco Attorneys have destroyed evidence of their
internal research into smoking and health. For example, at a time
when the company was resisting discovery in a number of personal
injury lawsuits, Brown & Williamson's General Counsel, J. Kendrick
Wells, recommended in a memorandum dated January 17, 1985, that
much of the company's biological research be declared "deadwood"
and shipped to England. He recommended that no notes, memos or
lists be made about these documents. Wells stated, "I had marked
certain of the document references with an X... which I suggested
were deadwood in the behavioral and biological studies area. I said
that the "B" series are "Janus" series studies and should also be
considered as deadwood." ("Janus" was a name of a project that
attempted to isolate and remove the harmful effects of tobacco.) Wells
further recommended that the research, development, and engineering
department also should undertake "to remove the deadwood from the
files."
117. Thus, the Tobacco Companies and the Tobacco Attorneys have
misused claims of Attorney/Client privilege to insulate CTR-funded
research projects and internal documents from disclosure to the public
and to government officials. This conduct demonstrates the falsity of
the Tobacco Companies' representations that they would jointly fund
objective research and report the results of that research to the public.
2. The "Mouse House" Disappears
118. In the 1960s, R.J. Reynolds established a facility in Winston-
Salem, North Carolina, to perform research on the health effects of
smoking using mice. Nicknamed the "Mouse House," R.J. Reynolds
scientists conducted research in a number of specific areas, including
studies of the actual mechanism whereby smoking causes emphysema
in the lungs.
119. The R.J. Reynolds lab made significant progress in
understanding this mechanism. Despite this progress, R.J. Reynolds
disbanded the entire research division in one day, and fired all 26
scientists without notice.
120. Several months before the 1970 closure and firings, R.J.
Reynolds attorneys collected dozens of research notebooks from the
scientists. The notebooks have still not been disclosed. One of the
researchers later stated about R.J. Reynolds' executives and lawyers
that "they like to take the position that you can't prove harm because
you don't know mechanism....And sitting right under their noses is
evidence of mechanism[.] What are they going to do with the stuff?
They decided to kill it."
121. Internally, an R.J. Reynolds-commissioned report favorably
described the Mouse House work as "the more important of the
smoking and health research effort because it comes close to
determining what was thought to be the underlying pathobiology of
emphysema." None of the work done at the "Mouse House" was
disclosed to the public.
122. In a similar incident, Philip Morris hired Victor DeNoble in 1980
to study nicotine's effects on the behavior of rats and to research and
test potential nicotine analogues. DeNoble, in turn, recruited Paul C.
Mele, a behavioral pharmacologist.
123. DeNoble and Mele discovered that nicotine met two of the
hallmarks of potential addiction -- self administration (rats would
press levers to inject themselves with a nicotine solution) and tolerance
(a given dose of nicotine over time had a reduced effect).
124. However, Philip Morris instructed DeNoble and Mele to keep
their work secret, even from fellow Philip Morris scientists. Test
animals were delivered at dawn and brought from the loading dock to
the laboratory under cover.
125. DeNoble was later told by lawyers for the company that the data
he and Mele were generating could be dangerous. Philip Morris
executives began talking of killing the research or moving it outside of
the company so Philip Morris would have more freedom to disavow
the results.
126. In April 1984, Philip Morris closed DeNoble's nicotine research
lab. DeNoble and Mele were forced abruptly to halt their studies, turn
off all their instruments and turn in their security badges by morning.
Philip Morris executives threatened them with legal action if they
published or talked about their nicotine research. According to
DeNoble, the lab literally vanished overnight. The animals were
killed, the equipment was removed, and all traces of the former lab
were eliminated.
127. DeNoble has testified "senior research management in
Richmond, VA., as well as top officials at the Philip Morris Company
in New York, continually reviewed our research and approved our
research." DeNoble also stated that these officials were specifically
told that nicotine was a drug of abuse.
128. In August 1983, Philip Morris ordered DeNoble to withdraw
from publication a research paper on nicotine that had already been
accepted for publication after full peer review by the journal
Psychopharmacology. According to DeNoble, the company changed
its mind because it did not want it own research showing nicotine was
addictive or harmful to compromise the company's defense in
litigation recently filed against it. He said that Philip Morris officials
had rightly interpreted the suppressed nicotine studies as showing
that, in terms of addictiveness, "nicotine looked like heroin."
129. Liggett & Myers also refused to disclose research by Dr. Ernest
Wynder showing the cancer causing propensity of cigarettes.
130. Brown & Williamson undertook its potentially sensitive research
on nicotine through a contractor in Geneva, Switzerland, and through
British affiliates at an English lab called Harrogate.
131. In 1963, Brown & Williamson debated internally whether to
disclose to the U.S. Surgeon General, who was preparing his first
official report on smoking and health, what the company knew about
the addictiveness of nicotine and the adverse effects of smoking on
health. Addison Yeamon, General Counsel, advised Brown &
Williamson to "accept its responsibility" and disclose its findings to
the Surgeon General. He said that such disclosure would then allow
the company openly to research and develop a safer cigarette.
132. Brown & Williamson rejected Yeaman's advice to make full
disclosure to the Surgeon General. A series of six letters and telexes
exchanged by Yeaman and senior British American Tobacco Company
official A.D. McCormick between June 28 and August 8, 1963,
document the company's decision not to disclose its research findings
to the Surgeon General. That research, some of which was later
characterized in a report in the Journal of the American Medical
Association as "at the cutting edge of nicotine pharmacology,"
preceded the main published reports from the general scientific
community by several years.
D. "Safer Cigarettes" Suppressed
133. Defendants could have designed and manufactured a safer
cigarette, but refused to do so. The need for a "safer" tobacco product
results from the harmful chemical compounds occurring in tobacco
products and/or formed as a result of burning. These compounds
include carbon monoxide, nicotine, nickel carbon dioxide, benzene,
hydrazine, fotmaldehyde, Polonium-210, ammonia, nicotine sulfate,
Freon II, hydrogen cyanide and certain liver toxins known collectively
as furans. More than forty (40) known carcinogens are found in
cigarette tobacco. Defendants artificially add chemicals and flavorings
to their products that increase toxicity and/or carcinogenicity.
134. Defendants have long understood that reducing or eliminating
nicotine from their products would hurt sales. As one company
researcher wrote in a 1978 report to Philip Morris executives: "If the
industry's introduction of acceptable low- nicotine products does
make it easier for dedicated smokers to quit, then the wisdom of the
introduction is open to debate."
135. Instead, the industry attempted to develop ostensibly safer ways
of delivering adequate doses of nicotine to create and sustain addiction
in the smoker.
136. Some members of the industry studied artificial nicotine or
nicotine analogues that would have the addictive and
psychopharmacological properties of nicotine without its dangerous
effects on the heart. Dr. Victor DeNoble was hired by Philip Morris,
in part, to research and develop a nicotine analogue.
137. Dr. DeNoble did discover such an analogue, but Philip Morris
chose to halt its effort to determine whether the nicotine analogue
could be used to make a safer cigarette.
138. Philip Morris also explored research to develop a safer cigarette,
or, in the words of one memorandum to the Board of Directors,
cigarettes with "superior physiological performance. " This
memorandum noted competitive pressures to produce "less harmful"
cigarettes. However, the memorandum was careful to state that, "[o]ur
philosophy is not to start a war, but if war comes, we aim to fight well
and to win." Philip Morris never broadly marketed such a "safer"
cigarette. Its documents state that "after much discussion we decided
not to tell the physiological story which might have appealed to a
health conscious segment of the market. The product as test marketed
didn't have good 'taste' and consequently was unacceptable to the
public ignorant of its physiological superiority." Subsequently, taste
was improved and Philip Morris attempted to promote the product.
However, "The imposition of FTC rules and the industry advertising
code took the starch out of the program...."
139. Brown & Williamson also understood that nicotine was the
essential ingredient in maintaining tobacco sales. The company
attempted to develop a "safer" cigarette which internal documents
described as "a nicotine delivery device," but did not market such a
cigarette in spite of promising test results. Brown & Williamson's
Project "Ariel" used a heating, as opposed to burning system. Its
Project "Janus" was intended to identify hazardous components of
cigarette smoke so they could be removed.
140. By the end of the 1970s, however, Brown & Williamson, in a
pattern that was repeated throughout the industry, closed its research
labs and halted all work on a safer cigarette.
141. R.J. Reynolds' efforts to develop a safer cigarette also focused
on delivering nicotine to the consumer without the harmful
constituents of tobacco smoke. In the late 1980s, R.J. Reynolds
developed and test marketed "Premier," a smokeless and virtually
tobacco-free cigarette which was, in essence, a nicotine delivery
system.
142. At Liggett & Myers, Dr. James Mold conducted tests to divide
the components of cigarette smoke into separate entities and to
interrupt the process that produces carcinogens by using a catalyst.
Liggett & Myers researchers were able to produce a so-called "safer"
cigarette, designated as the "XA Project" that eliminated the
carcinogenic activity on mouse skin. However, Liggett & Myers did
not want to be identified publicly as the source of the research behind
this non-carcinogenic "safer" cigarette.
143. Dr. Mold has provided the following overview of the XA Project
and its abandonment:
a. Dr. Mold stated that the XA project produced a safer cigarette. He
stated, "We produced a cigarette which was, we felt, commercially
acceptable as established by some consumer tests, which eliminated
carcinogenic activity..."
b. Dr. Mold stated that after 1975, all meetings on the project were
attended by lawyers. Lawyers collected notes after all meetings. All
documents were directed to the law department to cloak the documents
with the attorney-client privilege. He stated, "Whenever any problem
came up on the project, the Legal Department would pounce upon that
in an attempt to kill the project, and this happened time and time
again."
c. Dr. Mold was asked why Liggett did not market a safer cigarette.
He stated, "Well, I can't give you, you know, a positive statement
because I wasn't in the management circles that made the decision, but
I certainly had a pretty fair idea why ...[T]hey felt that such a
cigarette, if put on the market, would seriously indict them for having
sold other types of cigarettes that didn't contain this, for example...
[a]t a meeting we held in... New Jersey at the Grand Met
headquarters... at which the various legal people involved and the
management people involved and myself were present. At one point,
Mr. Dey... who at that time, and I guess still is the president of
Liggett Tobacco, made the statement that he was told by someone in
the Philip Morris Company that if we tried to market such a product
that they would clobber us."
144. Liggett had also obtained a patent for the process it had
discovered to produce its safer cigarette. The patent application
described the reduction in cancer in mice studies, prompting stories in
the media that Liggett was the first cigarette company to admit that
smoking caused cancer. Liggett responded by issuing a press release it
called a "Liggettgram" which stated: "Liggett and the cigarette industry
continue to deny, as they have consistently, that any conclusions can
be drawn relating such test results on mice in laboratories to cancer in
human beings. It has never been established that smoking is a cause of
human cancer. The laboratory experiments reported in the patent were
conducted for Liggett by an independent researcher, The Life Sciences
Division of Arthur D. Little, Inc."
145. At the time Liggett made this statement, Dr. Mold estimates that
Liggett had spent a total of $10 million on research involving mice, in
part to develop the safer XA cigarette. Liggett's internal reports on the
benefit of the XA, and the absence of increased risk of harm from the
additives used, specifically used animal studies as reliable indicators
of the health effect of the product on humans.
146. Liggett abandoned the project in furtherance of the conspiracy.
Liggett feared that the marketing of a "safer cigarette" would be, in
essence, a confession that its, and the industry's other cigarettes, were
not safe. Thus, one Liggett executive wrote that, "Any domestic
activity will increase risk of cancer litigation on existing products." In
addition, there was a threat of retaliation from industry leader Philip
Morris if Liggett broke ranks.
147. The industry was aware that consumer demand would support
"safer" products. Prior to adoption of the advertising Code,
companies made claims of reduced tar and nicotine content for their
products, which the public perceived as offering reduced health risks.
However, "the smoker of a filter cigarette [claiming reduced tar] was
getting as much or more nicotine and tar as he would have gotten from
a regular cigarette. He had abandoned the regular cigarette, however,
on the ground of reduced risk to health." The industry recognized a
difference between "health-oriented" cigarettes, which were never
marketed on a wide basis, and "health-image" cigarettes, such as low-
tar, low-nicotine products. The latter were a marketing tool, intended
to give the ill-using of a safer product.
148. The Federal Trade Commission Cigarette Advertising Guides,
adopted September 22, 1955 and modified March 25, 1966, did not
allow claims based on unsubstantiated health effects. However, it was
clear in the industry that the Guides could be modified if justification
was shown. Indeed, the 1966 modification of the Guides was based
on development of a method, albeit not without difficulties of its own,
of measuring tar and nicotine content. In the context of development
of a potentially less hazardous product, a Brown & Williamson
document by General Counsel Addison Yeaman states, "I would
submit that the FTC in the face of 1) the industry's research effort, 2)
the truth of our claims, and 3) the "public interest' in our filter, cannot
successfully deny us the right to inform the public." In truth, the
defendants used the FTC Guides as a shield behind which it concealed
its agreement not to compete. The voluntary agreement with the FTC
was characterized by the Consumers Union as being "to the industry's
advantage and to the public's disadvantage."
149. The Cigarette Advertising Code, adopted by the Defendants, was
another mechanism used to enforce the illegal agreement not to
compete on the basis of safety or health characteristics of tobacco
products. Among other provisions, it prohibits health claims in
industry advertisements unless the "Code Administrator," to whom all
cigarette advertisements are required to be submitted, approves of the
advertisement. The Code provided a mechanism to monitor and police
defendants' illegal agreement.
150. Reynolds also developed a "safer cigarette". Except for a brief
test in several cities, Reynolds did not market its safer product,
"Premier."
151. A memorandum authored by a Tobacco Attorney confirmed that
there was an industry-wide position regarding the issue of a safer
cigarette.
152. The 1987 memorandum was written in the context of the
marketing by Reynolds of its smokeless cigarette, Premier, which
heated rather than burned tobacco. The attorney wrote that the
smokeless cigarette could "have significant effects on the tobacco
industry's joint defense efforts" and that "[t]he industry position has
always been that there is no alternative design for a cigarette as we
know them." The attorney also noted that, "Unfortunately, the
Reynolds announcement . . . seriously undercuts this component of
industry's defense."
153. This fundamental position of the "industry" defense had been
identified much earlier. In 1970, a Tobacco Attorney wrote to DeBaun
Bryant, General Counsel at Brown & Williamson, expressing
concerns about some of the industry research into alternative products.
In critiquing the minutes of a conference, he stated: "It is our opinion
that statements such as [references to research into safer products,
products which are less biologically active, and to 'healthy cigarettes']
constitute a real threat to the continued success in the defense of
smoking and health litigation. Of course, we would make every effort
to 'explain' such statements if we were confronted with them during a
trial, but I seriously doubt that the average juror would follow or
accept the subtle distinctions and explanations we would be forced to
urge.... [E]mployees in both companies [Brown and Williamson and
British American Tobacco] should be informed of the possible
consequences of careless statements on this subject."
154. All defendants were keenly aware of the risk to the industry if
any of them sought a competitive advantage by developing and
marketing a safer product. The risk was avoided by agreeing to not
compete on that basis. As one industry representative testified: ". . . as
a company, we cannot position our products as being healthy. We've
already agreed that they are a risk factor [the 'agreement' referenced is
the industry's acceptance of the warning labels on cigarette packages]
. . . we wouldn't run any advertising that positions any of our
products as being healthier than others."
E. The Tobacco Industry's Knowledge of Nicotine's Addictiveness
155. An advertisement placed by Philip Morris in newspapers across
the country in April 1994, affirmatively represented that Philip Morris
does not "manipulate" nicotine levels in its cigarettes, and that "Philip
Morris does not believe that cigarette smoking is addictive."
156. R.J. Reynolds placed a similar advertisement in newspapers
across the United States in 1994 stating that "we do not increase the
level of nicotine in any of our products in order to addict smokers.
Instead of increasing the nicotine levels in our products, we have in
fact worked hard to decrease tar, and nicotine..." R.J. Reynolds'
advertisement then touted its use of "various techniques that help us
reduce the tar, (and consequently the nicotine) yields of our products."
157. In fact, Defendants have known of the difficulties smokers
experience in quitting smoking and of the tendency of addicted
individuals to focus on any rationalization to justify their continued
smoking. Defendants exploit this weakness and capitalize upon the
known addictive nature of nicotine. Nicotine addiction guarantees a
market for cigarettes. The addictive nature of the nicotine in cigarettes
virtually eliminates personal choice in those who become addicted.
Modern cigarettes as sold in Kansas are painstakingly designed and
manufactured to control nicotine delivery to the smoker.
158. Defendants have secretly known since at least the early 1960's of
the addictive properties of the nicotine contained in the cigarettes they
manufacture and sell. Sworn statements of former Philip Morris
scientists, Jerome Rivers, Dr. Ian L. Uydess and Dr. William Farone
belie the industry's denials, and industry documents are replete with
evidence of Defendants' historical knowledge of nicotine's
addictiveness.
159. In 1962, Sir Charles Ellis, scientific advisor to the Board of
Directors of British American Tobacco Company ("BATCO"), Brown
& Williamson's parent company, stated at a meeting of BATCO's
worldwide subsidiaries, that "smoking is a habit of addiction" and that
"[n]icotine is not only a very fine drug, but the technique of administration by smoking has considerable psychological
advantages...." He subsequently described Brown & Williamson as being "in the nicotine rather than the tobacco industry."
160. A research report from 1963 commissioned by Brown &
Williamson states that when a chronic smoker is denied nicotine: "A
body left in this unbalanced state craves for renewed drug intake in
order to restore the physiological equilibrium. This unconscious desire
explains the addiction of the individual to nicotine." No information
from that research has ever been voluntarily disclosed to the public; in
particular it was not shared with the Committee that was preparing the
first Surgeon General report and hence was not reflected in that report.
161. Addison Yeaman, General Counsel at Brown & Williamson,
summarized his view about nicotine in an internal memorandum also
in 1963: "Moreover, nicotine is addictive. We are, then, in the
business of selling nicotine, an addictive drug effective in the release
of stress mechanisms."
162. Internal reports prepared by Philip Morris in 1972 and the Philip
Morris U.S.A. Research Center in March 1978, demonstrate Philip
Morris' understanding of the role of nicotine in tobacco use: "We
think that most smokers can be considered nicotine seekers, for the
pharmacological effect of nicotine is one of the rewards that come
from smoking. When the smoker quits, he forgoes his accustomed
nicotine. The change is very noticeable, he misses the reward, and so
he returns to smoking."
163. From 1940-1970, the American Tobacco Company conducted its
own nicotine research, funding over 90 studies on the
pharmacological and other effects of nicotine on the body, 80% of all
biological studies funded by the company over this period. In 1969,
the American Tobacco Company even test marketed a nicotine-
enriched cigarette in Seattle, Washington.
164. In a 1972 document entitled "RJR confidential research planning
memorandum on the nature of the tobacco business and the crucial
role of nicotine therein," a R.J. Reynolds executive wrote: "In a
sense, the tobacco industry may be thought of as being a specialized,
highly ritualized, and stylized segment of the pharmaceutical industry.
Tobacco products uniquely contain and deliver nicotine, a potent drug
with a variety of physiological effects."
165. The industry's recognition of the extent to which nicotine - and not tobacco -- defines its product is illustrated in a 1972 Philip Morris report on a CTR conference, which stated:
a. "As with eating and copulating so it is with smoking. The physiological effect serves as the primary incentive, all other incentives are secondary. The majority of the conferees would go even further and accept the proposition that nicotine is the active constituent of cigarette smoke. Without nicotine, the argument goes, there would
be no smoking."
b. "Why then is there not a market for nicotine per se, eaten, sucked,
drunk, injected, inserted or inhaled as a pure aerosol? The answer,
and I feel quite strongly about this, is that the cigarette is in fact among
the most awe-inspiring examples of the ingenuity of man. Let me
explain my conviction. The cigarette should be conceived not as a
product but as a package. The product is nicotine."
c. "Think of the cigarette pack as a storage container for a day's
supply of nicotine... Think of the cigarette as a dispenser for a dose
unit of nicotine."
166. Documents from a BATCO study called Project Hippo,
uncovered only in May 1994, show that as far back as 1961, this
cigarette company was actively studying the physiological and
pharmacological effects of nicotine. Project Hippo reports were
circulated to other U.S. cigarette manufacturers and to TIRC,
demonstrating that at least some of the industry's nicotine research
was shared. BATCO sent the reports to officials at Brown &
Williamson and R.J. Reynolds, and circulated a copy to TIRC with a
request that TIRC "consider whether it would help the U.S. industry
for these reports to be passed on to the Surgeon General's
Committee."
167. Similarly, an RJR-MacDonald Marketing Summary Report from 1983 concluded that the primary reason people smoke "is probably the physiological satisfaction provided by the nicotine level of the product."
168. As recently as December 1995, the Wall Street Journal reported on an internal Philip Morris draft document analyzing the competitive market for nicotine products for the years 1990-1992. The report describes the importance of nicotine: "Different people smoke for different reasons. But the primary reason is to deliver nicotine into their bodies.... It is a physiologically active, nitrogen containing substance. Similar organic chemicals include nicotine, quinine, cocaine, atropine, and morphine. While each of these substances can be used to affect human physiology, nicotine has a particularly broad range of influence. During the smoke act, nicotine is inhaled into the lungs in smoke, enters the bloodstream and travels to the brain in about eight to ten seconds."
169. Recently disclosed handwritten notes dated 1965 from Ronald A. Tamol, who until 1993 was Philip Morris' director of research and brand development, refer to "minimum nicotine... to keep the normal smoker hooked."
170. In fact, in a decade long project, Brown & Williamson secretly developed a genetically engineered tobacco plant with a nicotine content more than twice the average found naturally in flue-cured tobacco. Brown & Williamson took out a Brazilian patent for the new plant, which was printed in Portuguese. Brown & Williamson and a Brazilian sister company, Souza Cruz Overseas, grew Y-1 in Brazil and shipped it to the United States where it was used 'in five Brown & Williamson cigarette brands sold in Kansas, including three labeled "light" When the company's deception was uncovered, company
officials stated that close to four million pounds of Y-1 were stored in
company warehouses in the United States.
171. As part of its cover-up, Brown & Williamson even went so far
as to instruct the DNA Plant Technology Corporation of Oakland,
California, which had developed Y-1, to tell FDA investigators that Y-
1 had "never [been] commercialized." Only after the FDA discovered
two United States Customs Service invoices indicating that "more than
a million pounds" of Y-1 tobacco had been shipped to Brown &
Williamson on September 21, 1992, did the company admit that it had
developed the high-nicotine tobacco.
172. In addition, cigarette manufacturers add several ammonia
compounds during the manufacturing process which increase the
delivery of nicotine and almost double the nicotine transfer efficiency
of cigarettes.
173. Brown & Williamson publicly denies that the use of ammonia in
the processing of tobacco increases the amount of nicotine absorbed
by the smoker. Nevertheless, the company's own internal documents
reveal that it is and its rivals use ammonia compounds to increase
nicotine delivery. As John Kreisher, a former associate scientific
director for CTR, conceded, "[a]mmonia helped the industry lower the
tar and allowed smokers to get more bang with less nicotine. It solved
a couple of problems at the same time."
174. The cigarette industry's manipulation of nicotine is particularly
harmful in view of its deceptive marketing of "light" or low-tar and
low-nicotine cigarettes to retain the health conscious segment of the
smoking market. Recent studies demonstrate that cigarettes advertised
as low tar and low nicotine have higher concentrations of nicotine, by
weight, than high-yield cigarettes. The Tobacco Companies
manipulate nicotine delivery levels in supposedly reduced tar and
reduced nicotine cigarettes through various strategies. For example:
a. Industry studies show that smokers tend to obtain close to the same
amount of nicotine from each cigarette despite differences in yield as
measured by the FTC smoking machine. Cigarette manufacturers have
designed "light" cigarettes in a deliberate attempt to circumvent FTC
methods of measuring tar and nicotine levels. By drilling nearly
invisible holes in the filter paper, the cigarette manufacturers have
prevented FTC smoking machines from accurately measuring the
actual tar and nicotine delivery to smokers, who naturally block the
tiny, laser-generated perforations with their fingers or lips, and
thereby receive greater tar and nicotine yields than indicated by FTC
measurements.
b. The FTC testing method does not distinguish between the slower
acting salt-bound nicotine and the more potent "free" nicotine that
ammonia helps release. An ammoniated cigarette that delivers more
potent nicotine to smokers measures the same as a cigarette with no
such additives.
175. The cigarette industry maintains that nicotine levels follow tar
levels. In the words of Dr. Alexander Spears, Vice Chairman of
Lorillard, in his 1994 testimony before the Waxman Subcommittee --
"[n]icotine [level] follows the tar level," and the correlation between
the two "is essentially perfect," and "shows that there is no
manipulation of nicotine." Dr. Spears neglected to mention to
Congress that in a 1981 study, not intended for public release, he
stated explicitly that low-tar cigarettes use special blends of tobacco to
keep the level of nicotine up while tar is reduced: "[T]he lowest tar
segment [of product categories] is composed of cigarettes utilizing a
tobacco blend which is significantly higher in nicotine."
176. R.J. Reynolds, Lorillard, the American Tobacco Company, and
the Tobacco Institute have similarly represented to the public and to
the FDA that the nicotine levels in their products are purely a function
of setting the tar levels of such products. Internal company documents
show, however, that the American Tobacco Company's
experimentation with adding nicotine to its tobacco was extensive --
extensive enough for American Tobacco Company executive John T.
Ashworth to instruct employees in a confidential memorandum: "In
the future, our use of nicotine should be referred to as 'Compound W'
in our experimental work, reports, and memorandums, either for
distribution within the Department or for outside distribution."
177. Tobacco industry patents also show that the cigarette industry
has developed the capability to manipulate nicotine levels in cigarettes
to an exacting degree. For example:
a. A Philip Morris patent application discusses an invention that
"permits the release . . . in controlled amounts and when desired, of
nicotine into tobacco smoke."
b. Another Philip Morris patent application explains that the proposed
invention "is particularly useful for the maintenance of the proper
amount of nicotine in tobacco smoke," and notes that "previous efforts
have been made to add nicotine to Tobacco Products when the nicotine
level in the tobacco was undesirably low."
c. A 1991 R.J. Reynolds patent application states that "processed
tobacco can be manufactured under conditions suitable to provide
products having various nicotine levels."
F. The Targeting of Children
178. Across the nation, the overwhelming majority of cigarette use
and addiction begins when users are children or teenagers. Eighty-two
(82%) percent of daily smokers had their first cigarette before age 18,
sixty-two (62%) percent of daily smokers had their first cigarette
before age 16, thirty-eight (38%) percent before the age of 14. Thus a
person who does not begin smoking in childhood or adolescence is
unlikely ever to begin. The younger a person begins to smoke, the
more likely he or she is to become a heavy smoker. Sixty-Seven
(67%) percent of children who start smoking in the sixth grade
become regular adult smokers and forty-six (46%) percent of
teenagers who start smoking in the eleventh grade become regular
adult smokers.
179. Smoking at an earlier age increases the risk of lung cancer and
other diseases. Studies have shown that lung cancer mortality is
highest among adults who began smoking before the age of 15.
180. Although young people frequently believe they will not become
addicted to nicotine or become long-term users of tobacco products,
they often find themselves unable to quit smoking. Among smokers
aged 12 to 17 years, a 1992 Gallup survey found that 70% said if they
had it to do over again, they would not start smoking and 66% said
that they want to quit. Fifty-one percent of the teen smokers surveyed
had made a serious effort to stop smoking -- but had failed.
181. Cigarette smoking among children and teens is on the rise. A
1995 National Institute of Drug Abuse study found that between 1991
and 1994, the proportional increase in smoking rates was greatest
among eighth graders, rising by 30%.
182. For many years, the defendants have engaged in a vast and
misleading promotional, public relations, and lobbying blitz which has
as its goal increasing the numbers of people addicted to nicotine in
cigarettes and decreasing the numbers of people who attempt or
succeed in quitting. Much of their efforts in this regard have been and
continue to be directed toward children. They have done so and
continue to do so in contravention of their duty not to make false
statements of material fact and their duty not to conceal such true facts
from the public. At the cost of countless lives, the defendants spend
billions of dollars every year misleading the public and promoting the
myth that smoking cigarettes does not cause cardiovascular disease,
lung cancer, emphysema and other diseases and that smokers live
healthy and vital lives. The Tobacco Defendants have at all pertinent
times presented and promoted smoking as an attractive, glamorous,
youthful, and relaxing pastime, associating it with movie stars,
athletes, and successful professionals.
183. Cigarettes are among the most promoted consumer products in
the United States. The Federal Trade Commission reported to
Congress that domestic cigarette advertising and promotional
expenditures rose from close to $4 billion in 1990 to more than $6
billion in 1993. Tobacco product brand names, logos, and advertising
messages are all-pervasive, appearing on billboards, buses, trains, in
magazines and newspapers, on clothing and other goods. The effect is
to convey the message to young people that tobacco use is desirable,
socially acceptable, safe, healthy, and prevalent in society.
Additionally, young people buy the most heavily advertised cigarette
brands, whereas many adults buy more generic or value-based
cigarette brands which have little or no image-based advertising.
Cigarette manufacturers, knowing that their advertising appeals to
young people, continue to use these same marketing techniques to sell
their products.
184. A July 1995 report by the California Department of Health
Services detailed the results of a survey of tobacco advertisements in
or around stores. In looking at almost 6,000 stores, it was found that
the total average tobacco advertisements and promotions per store was
25.26. Marlboro was the most frequently advertised and promoted
cigarette brand with an average of 10.15 advertisements and
promotions per store. Camel was the second most frequently
advertised and promoted cigarette brand and had an average of 4.84
advertisements and promotions per store. These two brands were the
most frequently advertised and promoted cigarette brands. Not
surprisingly, Marlboro, Camel, and Newport, the most heavily
advertised brands, are the leading brands smoked by children.
185. This same report also found that stores within 1,000 feet of a
school had significantly more tobacco advertising and promotions than
stores that were not near schools. Stores near schools were also more
likely to have at least one tobacco advertisement placed next to candy
or displayed at three feet or below. A significantly higher average
number of tobacco advertisements also were found on the exterior of
stores located in young neighborhoods - communities in which at least
one-third of the population in that zip code were 17 years of age or
less.
186. R.J. Reynolds has even identified the stores in proximity to the
youth market. R.J. Reynolds' Division Manager for Sales wrote all
R.J. Reynolds sales representatives in 1990 regarding the "Young
Adult Market" and asked them to identify what stores were in
proximity to colleges or high schools. A follow-up letter by the sales
division calls for a resubmitted list of Y.A.S. (Young Adult Smoker)
accounts using new criteria, focusing on all accounts located across
from, adjacent to, or in the general vicinity of high schools or college
campuses.
187. Despite these disturbing statistics, each of the Tobacco
Companies maintain that the effect of its pervasive advertising and
promotion of cigarettes is limited to maintaining brand loyalty and that
is has no role in encouraging adolescents to experiment with smoking.
188. The Tobacco Companies know that they attract underage
consumers to their products. For example, since 1988, R.J. Reynolds
has used a cartoon character called Joe Camel in its advertising
campaign. It has massively disseminated products such as
matchbooks, signs, clothing, mugs, and drink can holders advertising
Camel cigarettes. The advertising has been effective in attracting
adolescents, and R.J. Reynolds has knowledge of this fact but still continues the Joe Camel advertising campaign. As a result of the campaign, the number of teenage smokers who smoke Camel cigarettes has risen dramatically. Studies found that Joe Camel is almost as familiar to six-year old children as Mickey Mouse, is enticing thousands of teens to smoke that brand, and has caused Camel's popularity with 12-17 year olds to surge dramatically. R.J. Reynolds knew or willfully disregarded the fact that cartoon characters attract children.
189. The model who portrayed the "Winston Man" for R.J.
Reynolds' Winston brand cigarettes testified before Congress: "I was
clearly told that young people were the market that we were going
after." He further testified "it was made clear to us that this image was
important because kids like to role play, and we were to provide the
attractive role models for them to follow.... I was told I was a live
version of the GI Joe...."
190. An R.J. Reynolds affiliate studied in detail the motivations of
young smokers. A "Youth Target" study was the first of a planned
series of research studies into the lifestyles and value systems of
young men and women in the 15 to 24 age range, the stated purpose
of which was to "provide marketers and policy makers with an
enriched understanding of the mores and motives of this important
emerging adult segment which can be applied to better decision
making in regard to products and programs directed at youth." The
study focused on the "primary elements of lifestyles and values among
the youth of today," in learning how to market products to children
and teens.
191. Defendants used this information in devising advertising to create
a mental image associating smoking with health, glamorous and
athletic lifestyles, and with success and sexual attractiveness. Their
advertising and marketing campaigns increase demand for tobacco
products among young people. The ease with which children and
teenagers can obtain cigarettes from vending machines, assures that
there is a ready supply to meet this demand. It has been shown
repeatedly that cigarette vending machines (even those located in bars
and other supposedly adult locations) are readily available to children
and teenagers. Within a short period of time, the young smoker
becomes physiologically and emotionally dependent, i.e., addicted to
tobacco. Later, as the maturing smoker begins to wish he or she could
quit, advertising reinforces the practice and seeks to minimize health
concerns, create doubt and confusion, which are used by smokers as
an excuse to avoid the pain and discomfort of attempting to break their
addiction to nicotine.
192. One of the best examples of this was the transformation of
Marlboro cigarettes, from a red-tipped cigarette for women to the
cigarette for the "macho cowboy." By changing advertising imagery,
Philip Morris was able to tap into a wholly new and different market.
In 1950, R.J. Reynolds was the king of the cigarette business. It sold
more cigarettes than any other company. Philip Morris, though doing
well on the basis of its fraudulent health oriented advertising, was still
far behind. In 1981, Philip Morris overtook R.J. Reynolds, and each
year has extended its lead, by developing an effective marketing
campaign for recruiting young new smokers to its brands. The image
created by the Marlboro man captured the adolescent imagination,
leading to experimentation with that particular cigarette and eventual
addiction due to the manipulation by Philip Morris of the nicotine and
other ingredients in the cigarette. The children and teenagers who
started smoking Marlboro became tenaciously loyal customers. Soon,
Marlboro became the "gold standard" of cigarettes among teenagers.
Through the year 1988, nearly three-fourths of teenage smokers used
Marlboro.
193. At about the time it lost market leadership to Philip Morris, R.J.
Reynolds dedicated itself to a ruthless advertising campaign
encouraging children and teenagers to smoke. One of the key elements
of the R.J. Reynolds' strategy for attracting children was to reposition
many of its cigarette brands to younger audiences. Just as Marlboro
was repositioned from the women's market to the male market, by a
new advertising campaign, R.J. Reynolds has positioned its cigarette
advertising campaigns to younger and younger audiences using a
succession of advertising images of men engaged in extraordinary
feats of physical and athletic achievements.
194. R.J. Reynolds' Vantage cigarettes entered the 1980s as a brand
targeted at the health conscious adult smoker. Advertisements were
intended to assuage fears of lung cancer and other diseases and give
the concerned smoker arguments for rationalizing their continuation of
the addiction. Through multiple-advertising transmogrifications,
Vantage cigarettes have been progressively repositioned to ever-
younger audiences. During the mid-1980s, this advertising campaign
featured young, successful professionals (including architects, fashion designers, lawyers, etc.) with the slogan "The Taste of Success."
These ads promoted the implication that smoking is helpful -- if not
essential-- to success or prominence. In the late 1980s, the advertising
theme for Vantage cigarettes began to feature professional-caliber
athletes and auto racers. These advertisements depict physical activity
requiring strength or stamina beyond that of everyday activity. The
obvious implication is that smoking does not harm you.
195. During the 1980s, advertising for Salem cigarettes also became
more youth-oriented. Whereas the dominant advertising theme for
Salem cigarettes used to be clean, fresh country air, during the 1980s,
Salem ads were populated by muscular surfers and bikini clad
women, partiers, and other attractive, adolescent role models. Another
successful advertising campaign targeted at young people is the
Lorillard Tobacco Company campaign promoting Newport cigarettes.
Newport ads frequently show men and women in sexually suggestive
positions always having fun, using the slogan "Alive With Pleasure."
196. Another successful advertising campaign has been the "You've
Come A Long Way Baby" campaign, promoting Virginia Slims
cigarettes. One of the most important psychological needs of most
adolescent girls is to become independent from their parents. By
associating smoking with women's liberation, Philip Morris intended
to create in the minds of teenage girls, the vision of smoking as a
symbol of autonomy and independence. Ads for Virginia Slims and
other "feminine" cigarettes prey upon the natural and common
insecurity experienced by adolescents, by portraying the cigarette as a
crutch and a symbol of superiority. Perhaps the most acute
psychological need of adolescence is to fit in, to be accepted, and to be
popular. Ads for Philip Morris' Benson & Hedges cigarettes
developed an image of smoking as a happy pleasure to be shared in
the company of others and the easy road to instant acceptance within a
group.
197. In today's culture, many teenage girls perceive that a prerequisite
to popularity is to be thin. Philip Morris and other cigarette companies
capitalize upon this perception by presenting cigarette smoking as a
suitable alternative to diet for being thin. Virtually every "feminine"
cigarette includes words like slim, light, super slim, ultra light, etc.
The photographic imagery in cigarette advertising that targets young
females universally portrays attractive young women in glamorous
outfits. Smoking is thus associated with being sexy and beautiful.
198. Many teenage boys fantasize about owning a powerful
motorcycle. For this reason many cigarette brands have used
motorcycle imagery to encourage teenage boys to smoke. Many
cigarette ads that target young boys glamorize high risk activities like
hang gliding, motorcycle racing, and mountain climbing. Cigarette
makers do this deliberately to undermine awareness that smoking is
dangerous. In its campaign to attract adolescent boys to become
smokers, the R.J. Reynolds Tobacco Company has made extensive
use of risk taking and danger in its advertising. By glorifying risk-
taking, these ads have a more insidious purpose. How a person
estimates the magnitude and likelihood of a risk can be significantly
affected by what it is compared against. By portraying dangerous
activities like hang-gliding, mountain climbing, and stunt motorcycle
riding in tobacco advertising, R.J. Reynolds minimizes the dangers of smoking in adolescent minds.
199. The great success that R.J. Reynolds has had in its effort to
overtake Philip Morris in the youth market is principally due to the
"Joe Camel" cartoon character. This campaign was inaugurated in the
United States in 1987 to commemorate the 75th anniversary of Camel
cigarettes. In the first ads, the camel leered out over the ad saying "75
Years and Still Smoking." The implication is obvious. It soon became
evident that "Joe Camel" would strike a responsive chord among
children and teenagers and has been used by R.J. Reynolds to target
children to get them to start smoking as early as possible, so they can
become addicted to nicotine at the earliest age possible. R.J. Reynolds
has more than tripled its advertising expenditures for Camel cigarettes
since 1988, utilizing themes like "Joe Camel" that are guaranteed to be
attractive to young people at high risk of becoming smokers.
200. When R.J. Reynolds began the Joe Camel cartoon campaign,
Camel's share of the children's market was only O.5%. In just a few
years, Camel's share of this illegal market has increased to 32.8%,
representing sales estimated at $476 million per year. Anther
indication of the phenomenal success of this marketing campaign is
the fact that in a recent survey of six year olds, 91% of the children
could correctly match Joe Camel with a picture of a cigarette, and both
the silhouette of Mickey Mouse and the face of Joe Camel were nearly
equally well-recognized by almost all children surveyed.
201. The themes within cigarette advertising are not the only feature of
tobacco marketing that betray the real target. The location and
placement of those ads further reveal that children are the intended
target. During the decade of the 1980s, there was a steady migration
of cigarette advertising into youth-oriented publications. Magazines
with sexually-oriented themes and those concerning entertainment and
sporting activities had the highest concentration of cigarette ads. For
many of these magazines, teenagers comprise a quarter |